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 New active pharmaceutical ingredients (APIs) continue to be discovered from the 
natural world. These compounds can be further developed into a range of useful 
products such as drugs, supplements, or cosmeceuticals. To determine the biological 
target of the API, the new compounds are evaluated for their biological activity through a 
combination of in silico, in vitro, and in vivo analyses. These results will determine where 
the molecular target tissue is located for the API. However, identification of the target is 
only the beginning of pharmaceutical and cosmeceutical development. A common 
roadblock in the development of products is the evaluation and manipulation of the 
permeability of an API through biologically relevant membranes.  
 Multiple in vitro methods to assess permeability have been developed to predict 
how APIs will interact with membranes such as the gut, skin, and blood brain barrier 
(BBB).  Utilizing a combination of prediction methods for APIs can allow early indication 
of drug likelihood, including fundamental permeability factors such as LogP, the measure 
of lipophilicity. Additionally, the physicochemical properties of the molecule of interest 
can be evaluated to compare the attributes of the API to other drugs and supplements.  
 Natural product libraries of varying complexity were evaluated for biological 
activity followed by permeability analysis and drug likeliness. Samples include crude 
plant extracts, pre-chromatography fractions from a cyanobacterial bloom, and the pure 
compounds unnarmicin D and cannabidiol (CBD). Through these workflows, two new 
anti-inflammatory metabolites have been discovered, a new opioid ligand has been 
identified, and permeability coefficients for a common cosmeceutical have been 
v 
evaluated. Early integration of these permeability methodologies will allow better pre-
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CHAPTER 1: JUSTIFICATION OF RESEARCH 
 
INTRODUCTION 
 Natural products continue to be the driving force in the discovery of new 
small molecule therapeutics.1 Thousands of new molecules are discovered each year 
providing an indispensable resource for new chemical diversity, including new agents 
with previously undescribed mechanisms of action for quickly evolving diseases.2 
Drug discovery from natural products often involves either an in-depth investigation of 
the secondary metabolite arsenal of a single organism, or screening a library of 
natural product extracts, fractions, or pure compounds against a therapeutic target. 
Screening natural product libraries paired with efficient natural product workflows has 
led to new therapeutics with novel mechanisms of action for diseases like cancer, 
HIV, and bacterial infections.3-5 However, many natural product drug leads are 
structural complex, which can result in unfavorable pharmacokinetic profiles. Poor 
solubility, permeability, and stability of molecules is a common roadblock preventing 
these metabolites from being developed into a drug, supplement, or cosmeceutical 
product.5 
There are a variety of methodologies that can be implemented to screen natural 
product libraries. Screening crude natural product extracts requires little resources for 
preparation but require large amounts of resources for purification and identification of 
active metabolite. Pre-fractionated libraries can shorten the time to hit identification, 
and pure compound libraries take many resources to produce, but hit identification is 
rapid.6,7 
 Once an active metabolite has been identified through screening platforms, the 
drug-likelihood of the compound needs to be evaluated. Many of the 
pharmacokinetic and pharmacodynamic parameters will require in vivo analysis in 
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animal models. However, if safety and efficacy testing is possible outside of an 
animal model for early indications of drug-likelihood, such assays should be 
prioritized. The lead compounds’ permeability through biologically relevant 
membranes is important in determining if the compound will reach the target organ, 
and how quickly it will reach the target. This information can then be used to 
determine mode of administration and dosing regimen. In silico and in vitro 
methodologies have been developed for early screening of permeability through the 
skin, gut, blood brain barrier (BBB), and cells.  Despite the current mechanisms to 
increase permeability and bioavailability of lead compounds, early screening of drug-
likelihood using in vitro and in silico methods can eliminate weak drug candidates. 
 Drug permeability through biological membranes is integral in understanding and 
assessing potential leads in the drug development pipeline. Many protein drug 
targets of interest are located intracellularly; therefore, the compound must pass the 
cell membrane and reach the cytosol to interact with the target. The rate of diffusion 
will depend on the physiochemical parameters of the molecule, the characteristics of 
the membrane of interest, active transport mechanisms, and the presence of efflux 
pumps that may remove the compound once it has passed the membrane.8 
 There are several generalizations or “rules” that predict how likely a compound is 
to become an orally bioavailable drug by comparing the relationship between 
compound structure and common drug-like properties.9 Dr. Christopher Lipinkski’s 
rule of 5, which considers a compounds molecular weight (MW), hydrogen bond 
donors and acceptors, and hydrophobicity or logP is often used as the gold standard 
of rules.10 However, this physiochemical analysis primarily focuses on the passive 
nature of these molecules and in biological systems there are active transport 
mechanisms that can allow a drug to reach the biological target.  
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 Natural products are biosynthesized within organisms and therefore resemble 
endogenous ligands utilized in the physiochemical processes of other organisms. 
This element allows more natural products to be actively transported across 
membranes compared to synthetic alternatives.11 This attribute can be both 
beneficial in the case of theophylline, a drug isolated from coca beans and used for 
respiratory issues such as COPD which uses active transport mechanisms to pass 
into the gut.12 Similarly, from a toxicokinetic perspective, transportation could be 
harmful, cyanobacteria toxins of the microcystin family which are large relatively 
hydrophilic peptides can accumulate in the liver and cause severe damage to 
humans and animals. These molecules are transported by organic-anion transporting 
polypeptides (OATPs) that are mainly expressed on hepatocytes and would not be 
able to cause cellular damage without being actively transported into the cells.13 For 
this reason, and others such as increased rigidity of natural compounds, natural 
products do not always conform to Lipinski’s rules.14 Despite the discrepancy with 
Lipinski’s rules and natural products, Quinn and colleagues found that 80% of natural 
products had less than two violations to the developed rules, suggesting this is still a 
valuable method for early evaluation of the structure-clinical drug relationship.9 
A targeted approach to screening libraries can be taken by employing in vitro 
permeability assays such as the parallel artificial membrane permeability assay 
(PAMPA) and the Franz cell diffusion assay early in the developmental pipeline.15-17 In 
silico methods using the physiochemical attributes of the compound and well 
established “rules” of drug-likeliness can be utilized to predict potential 
bioavailability.18-21 These methods can be applied to neuropharmacological drug 
candidates as well as other compounds through biologically relevant membranes 
such as the gut and the skin.  
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There is a significant need to employ permeability analysis methodologies early 
in the drug development pipeline, as well as the supplement and skincare industries 
to produce targeted products with predictable biological responses. This dissertation 
emphasizes the development of crucial methodologies for assessing and predicting 
the permeability of natural products from crude extracts to pure compounds. Early 
integration of these methodologies in drug development workflows will allow for better 
pre-clinical outcomes for new drug candidate and have an important impact in drug 
discovery and development. 
 The overall theme of this work is the pairing of unique natural product 
screening libraries, constructed by myself and coworkers, with permeability assays 
using biomimetic membrane systems for improved drug lead identification. In chapter 
one of this dissertation, I will discuss the development of the Principle Rhode Island 
Secondary Metabolite (PRISM) library and the subsequent screening of medicinal 
plant extracts against various microbial pathogens. The latter part of this chapter will 
also highlight the tulip tree (Liriodendron tulipifera); a plant that produces a unique 
antibacterial compound that is effective against methicillin resistant Staphylococcus 
aureus. Chapter two will expand the scope of screening to a library comprised of 
cyanobacterial chromatography fractions, a rarified collection of microbial specialized 
metabolites in comparison to a crude extract library. Two new metabolites in the 
micropeptin family were identified through these workflows that reduce 
neuroinflammation in BV2 microglial cells. The fourth chapter will discuss the pure 
compounds Unnarmicin D, which was identified as a potential neurotherapeutic and 
opioid receptor ligand through screening of a pure compound library comprised of 
cyanobacterial metabolites from Trichodesmium thiebautii. The last chapter will 
integrate new methods for studying the passive permeability of the Cannabis sativa 
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metabolite cannabidiol, a metabolite from the Cannabis sativa plant through the skin 
using multiple in vitro approaches.  
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ABSTRACT 
Chemical screening libraries often feature natural product extracts (NPEs) due to the 
intriguing biological activities they possess, and the structural diversity found in their 
individual components. A research project originally designed to create an extract library 
of every specimen in the University of Rhode Island (URI) Heber W. Youngken Jr. 
Medicinal Garden soon turned into a laboratory-based teaching project in which upper-
division undergraduate students generated and analyzed extracts in an academic mini-
semester project. Additionally, motivated upper-division undergraduates carried out 
independent research isolating biologically active molecules. Hands-on laboratory 
activities enhanced students’ knowledge of methodologies and workflows associated 
with extract analysis and biological evaluation of botanical extracts. The synergy of the 
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Natural products comprise the majority of our pharmacopeia, with 73% of all new 
approved drugs from 1981-2014 being natural products, natural product derivatives, or 
drugs inspired by natural products.1 In the decade between 2000 and 2010, 38 natural 
product-derived drugs were approved for use in various medical indications.2 Of the 
more than 100 natural product-derived drugs in clinical development during this time 
period, 91 were plant derived.2 The historical and cultural uses of natural products gives 
herbal and botanical sources of new drugs somewhat of an advantage over unfamiliar 
sources of natural products. Botanical-based discovery is frequently “experience driven”, 
for instance an herbal treatment is associated with symptom alleviation, which is often 
noted in traditional Chinese medicine (TCM) or ayurvedic medicine, which sets the stage 
for the isolation and characterization of an active component. Herbal treatments include 
whole plant extracts, mixtures of plant extracts, and the healing potential of functional 
food.3 These multifunctional uses necessitate that analytical procedures improve quickly 
to identify potential active components in extracts, and that diverse biological assays are 
utilized to determine therapeutic potential. The paired desires to 1) create the Principle 
Rhode Island Secondary Metabolite (PRISM) library from extracts of plants from the URI 
Heber W. Youngken Jr. Medicinal Garden and 2) to provide upper-division 
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undergraduate students greater hands-on experience and research independence came 
together to form the foundation of this educational and training experience. This 
laboratory course enabled students to comprise our “workforce”, and to carry out 
important procedures and workflows in natural product chemistry and medicinal 
chemistry including HPLC (HPLC-UV), mass spectrometry (LC-MS), and biological 
assays (DPPH antioxidant assay). At the end of the course and independent study, 
students were better prepared for a career in the pharmaceutical sciences, and they 
were excited to be part of a larger research project with a potential impact in drug 
discovery. 
RESEARCH QUESTIONS 
We began this endeavor at the research laboratory level, asking ourselves if it was 
feasible to generate an extract library of the greater than 200 specimens in the Heber W. 
Youngken Jr. Medicinal Garden at URI. The goal was to create a collection of extracts 
comprising the Principle Rhode Island Secondary Metabolite (PRISM) library, which 
could then be used by internal and external partners as a chemical screening tool. 
Additionally, a main goal was to acquire information on each extract including the 
complexity of metabolite composition, the relative quantity of known medicinal 
compounds, and biological activities of extracts. Furthermore, we wanted students to 
modify and optimize chromatography methods during metabolic profiling. The process of 
library construction, from harvesting and vouchering specimens, to generating extracts, 
and acquiring biological and analytical information could be completed under the 
umbrella of an upper-division undergraduate medicinal chemistry laboratory course. The 
existing infrastructure of the medicinal chemistry course was easily altered to 
accommodate a seven-week long research project dedicated to generating PRISM 
library extracts and acquiring necessary analytical information on extracts. Students 
gained experience in literature review, chromatography, spectroscopy, and spectrometry 
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techniques in the pharmaceutical industry, and they were able to participate in a 
research endeavor, which is presently continuing in an academic research laboratory. 
Select highly motivated students continued to work on library construction via 
independent study projects in which they completed bioassay-guided isolation to purify 
plant metabolites. 
METHODS AND FRAMEWORK 
Two separate student cohorts participated: upper-division undergraduate students in 
a laboratory course (teaching lab), and upper-division undergraduate students taking 
part in an independent study project in an academic research laboratory (research lab). 
The independent study project took place outside of the mini-semester course with 
several students who had participated previously in the mini-semester engaged in 
independent study. For the laboratory course, 46 students were introduced to the mini-
semester objectives and workflows in a lecture setting. These students were enrolled in 
BPS 451, Techniques in Medicinal Chemistry and Molecular Biology, which is an upper 
division undergraduate laboratory course in the Pharmaceutical Sciences major at the 
University of Rhode Island. This course is a requirement in the Bachelor of Science in 
Pharmaceutical Science major and students in the course have taken General and 
Organic Chemistry as well as General Biology. The students have also taken more 
specialized courses in pharmaceutical sciences such as Medicinal Chemistry, 
Pharmaceutical Pharmacology, and Drug Metabolism and Bioanalysis. Students spend 
six hours a week in the lab for the course in two three-hour blocks. Each day in the lab 
began with a “pre-lab” component in which the concept of the PRISM library was 
introduced and the theory of that week’s experiments were discussed in detail. When the 
course moved into HPLC and mass spectrometry, we began a “post-lab” component in 
which data were reviewed and new methods were developed. The post-lab was done as 
an entire class with each group presenting their findings. This approach allowed for 
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repetition and reinforcement of important ideas for each topic discussed. The students 
were first assigned into groups of 3-4 students and each group harvested a plant 
specimen from the garden. Preference was given to those plants that had not yet been 
extracted, specimens prioritized for further study in the research lab, and plants that 
were currently in bloom. Each botanical specimen selected for extraction and addition to 
the PRISM library results in four extracts. Aerial and root portions are separated, and 
each of those portions is divided in two. Aerial and root samples are extracted in both 
organic (methanol) and aqueous (water) solvents. Thus, while the Youngken Garden 
houses over 200 medicinal plants, the PRISM library will contain approximately 800 
extracts. The approach in the teaching lab was to follow this framework. However, 
certain specimens such as Aloe vera were not removed from the garden, and thus did 
not have a root sample, and only aerial portions were analyzed. Specimens were dried 
for one week and a portion of each specimen was placed in a voucher library housed in 
the URI Herbarium. When specimens were ready for processing, each group was given 
an ‘extract notebook’ sheet to complete, indicating important information on each 
extraction. The sheets are housed in the laboratory of the corresponding author. A major 
portion of the initial extract collected in the teaching lab was reserved for the PRISM 
library (research lab). Each crude extract was placed into a vial in a barcoded Micronic 
storage system, while 10 mg/mL solutions of each extract in DMSO were generated for 
biological assays, and solutions were placed into 96-vial Micronic storage system. All 
sample barcodes were entered into a database. In the teaching lab, students continued 
with the remaining minor aliquot of extract for further teaching laboratory studies. 
Throughout the remaining six weeks, students completed concentration of extracts in 
vacuo, DPPH antioxidant assays on extracts, SPE fractionation, and additional DPPH 
antioxidant assays using the SPE fractions. Fractions that possessed the strongest 
antioxidant activity were further analyzed using HPLC-UV and LC-UV-MS.  (Table 1). 
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Data and results from these experiments are shown in the Supporting Information 
document. 
 
T1 1 Table 1. Topics covered by weeka 
Week Topic Techniques 
1 
Introduction to PRISM Library, 
Laboratory Safety, Plant Harvesting 
& Vouchering 
Voucher specimen preparation 
2 Extraction & Concentration 
Extracting solids, filtration, rotary 
evaporation 
3 Bioassay & Chromatography DPPH assay & SPE fractionation 
4 
Analytical Chromatography & Method 
Development 
HPLC 
5 Metabolic Profiling Mass spectrometry 
6 Compound Identification MS & NMR 
7 
Lab Presentation & Report 
Preparation 
Scientific communication & writing 
aEach week students contributed two 3 hour laboratory periods 
 
Certain highly motivated upper-division undergraduate students were selected to 
contribute to the PRISM library in an independent research setting. These students 
continued to add extracts to PRISM, performed analytical procedures, and they 
additionally completed bioassay-guided isolation projects to isolate and characterize 
pure plant metabolites with anti-bacterial activity. These student groups made significant 
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contributions to PRISM library construction and utilization (Figure S1) while practicing 
key competencies for natural product chemistry workflows. 
FINDINGS 
The teaching lab class was divided into morning and afternoon sessions. There was 
specimen overlap between the sessions, which validated the reproducibility of our 
workflows, and ultimately led to seven additional extracts in the PRISM library. 
Successful completion of the course entailed identifying an initial extract with the most 
potent antioxidant activity (methanol vs. aqueous or aerial vs. root). As medicinal plants 
contain many polyphenols and other organic compounds with antioxidant activity,4 each 
group identified an extract with which to continue (Figure S2). The remainder of the 
course was devoted to fractionating the active extract (SPE fractionation) and performing 
bioassays on the more rarefied active subfractions (DPPH assay), optimizing HPLC 
methods (HPLC-UV), and identifying putative metabolites responsible for the antioxidant 
activity (LC-UV-MS). SPE fractionation afforded each group an active antioxidant 
fraction (Figure S3), and while often subtle, groups were able to accomplish HPLC 
method optimization to better resolve metabolite composition (Figure S4). The post-lab 
portion of the class aided in students’ understanding of method optimization and it 
ensured that each group received feedback from peers, teaching assistants, and the 
instructor. The post-lab discussion additionally aids in filling laboratory time while 
passive experiments such as MS acquisition take place. Student groups were able to 
make at least one putative metabolite identification for components in five out of the 
seven plant specimens (cf. Table 2 and Figure S5), and morning and afternoon groups 
generally showed similar activity and metabolite profiles and made identical compound 
identifications (Figure S6-S10). An example of the composition analysis on an aloe 








T1 2 Table 2. Specimens analyzed and major compound(s) identifieda 
Specimen Common Name Putative Compound 
Identifications 
Aloe vera Aloe Aloin A, Aloin B 
Hypericum 
perforatum 
St. John’s Wort Quercetin, Isoquercetin 







Rosemary Rosmarinic Acid 
Humulus lupulus Hops Isoquercetin 
Echinacea purpurea Echinacea No putative identifications made 
aAnalysis performed on single quadrupole MS system with polarity switching 
enabled. 
 
1H NMR experiments were carried out on chromatography fractions in a previous 
iteration of the course using a 300 MHz Bruker NMR spectrometer. We determined that 
the complexity of NMR signals in sample mixtures posed too difficult an analytical 
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experience for upper-division undergraduates. In the current course format, major 
metabolites that are known to be produced by plants specimens and some of those 
putatively identified from chromatography fractions were purchased from commercial 
sources when available. Students analyzed these pure molecules via 1H NMR analysis 
and assigned resonances to their structures. 
Upper division undergraduate students in the research laboratory were instrumental 
in development of the PRISM library. Each semester, one student focused their 
independent research on producing extracts from the garden. These students generated 
an average of 30 extracts per research semester. Other students in the research 
laboratory focused on harvesting and vouchering plants specimens, and generated five 
extracts on average per semester. These students were able to cross-train each other 
on matters concerning the routine procedures in generating the extract library. Additional 
questions were sent to the graduate student on the project or the faculty mentor. During 
bioassay research in the laboratory, although there are limitations with undergraduates 
working with pathogens (methicillin-resistant Staphylococcus aureus, MRSA), the 
students were instrumental in fractionating extracts of interest. For separations, students 
used flash chromatography and time-based semi-preparative HPLC collections. After 
this rarefication procedure, they assisted with HPLC and MS analysis of the fraction of 
interest, and assisted with dereplication. This resulted in the isolation of several pure 
plant metabolites, which showed potent anti-MRSA activity. These results will be more 
elaborately discussed in a future research article 
LIMITATIONS 
While the course overall was deemed a success based on the bioassay and mass 
spectrometry results, there are improvements we plan to implement in future iterations of 
the course. The first is a course expansion beyond seven weeks. This will allow more 
hands-on experience with HPLC and mass spectrometry. Future experiments can be 
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designed to compare metabolites between plant parts (aerial vs. roots), or to focus on a 
distinct group of medicinal plants (ex. Euphorbia species). Additionally, mass 
spectrometry experiments will be designed for implementation earlier in the course. It is 
possible that the groups studying echinacea and comfrey would have identified major 
metabolites in whole extracts, when they were not able to do so from rarefied 
chromatography fractions with fewer metabolites present than those found in crude 
extracts. The URI College of Pharmacy is fortunate to have a world-renowned medicinal 
garden, an experienced garden coordinator, and an exceptional teaching laboratory with 
four HPLC-UV systems and two LC-UV-MS systems for analysis. This infrastructure 
affords a course framework with many opportunities for hands-on learning by students. 
However, the framework of the course can be easily modified for teaching labs with 
fewer analytical instruments and for those lacking a plant garden. Herbal and botanical 
samples can be purchased or collected. University herbariums can be a resource for 
specimens and pending a permit, collections can often be carried out in public lands. 
Additionally, there are commercial sources for ornamental and medicinal seeds. Many 
common weeds and invasive plants contain unique and understudied metabolites.5,6 
Specimen libraries can be created from terrestrial or aquatic plants, bacteria, and fungi, 
which would also incorporate important cultivation techniques. A focus on 
chromatography and spectrometry can shift to bioassays, which are generally 
inexpensive, high throughput, and informative. While there are limitations, a mini-
semester course of experiments building towards a final report has distinct advantages 
over a laboratory course consisting of disparate weekly endeavors. The mini-semester 
promotes integration, project ownership, and the development of background knowledge 
that mirrors the skills needed to excel in pharmaceutical industry positions, and to 
enhance workforce development. Rather than learning each skill separately, students 
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are able to integrate a variety of analytical techniques to ultimately build a metabolic 
profile for a plant that grows in the Heber W. Youngken Jr. Garden. 
IMPLICATIONS 
Incorporating laboratory classes and independent study into the generation of the 
PRISM library had several positive outcomes for students in the teaching lab: 
1. Students experienced “buy-in” by contributing to a research project that extended 
beyond the course itself. 
2. Introduction to integrative and multidisciplinary approaches in analytical chemistry 
and biology in a discovery context. 
3. Introduction to the concept of de-replication (limiting compound re-discovery) with 
respect to natural product chemistry research. 
4. Enhancing the ability to communicate and write scientifically by completing 
presentations and laboratory reports.  
5. Replacing the concepts of being “right or wrong” with a more nuanced approach, 
which mimics academia and industrial project workflows. 
Additional outcomes for advanced students in the research lab: 
1. Exposure to more complicated workflows under supervision. 
2. Continued project when laboratory courses were not in session. 
3. Leadership development through near-peer mentoring, as experienced 
undergraduate students train and assist new students under the direction of both a 
graduate student and faculty mentor. 
4. Scholarly development by contributing to journal articles, and gaining experience in 
manuscript preparation and submission during their undergraduate studies. 
 
While the corresponding author has been an instructor in BPS 451 since 2016, 
specimens from the medicinal garden were not introduced until 2018. In 2018, the 
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course began to evolve into the mini-semester project in which student groups focused 
on acquiring analytical information on one plant specimen from the garden. The creation 
of the PRISM library began in 2019 and its integration into the course framework is the 
subject of the current report. We do think that the mini-semester project concept and the 
increased focus on active and collaborative learning has led to better student learning 
outcomes. However, we plan to include more targeted assessment questionnaires in 
future iterations of the course, which will explore the impact of this course on student 
learning, such as learning specific skills in spectrometry and spectroscopy. With respect 
to independent study students in the research laboratory, we will gauge student 
outcomes based on participation as authors in research articles and presentations as 
well as employment in industry or graduate school. While this approach to a laboratory 
mini-semester was inspired by other teaching laboratories published by this journal,7-9 
there are significant departures from previously published work. This teaching laboratory 
is paired with independent study, which incorporates and accelerates inquiry-based 
learning, personalized learning, and peer-to-peer mentoring. The deliverables from this 
course transfer directly to the academic research laboratory setting. Furthermore, the 
incorporation of mass spectrometry in the teaching laboratory is highly relevant to 
pharmaceutical scientist training in areas such as structure characterization,10 
composition analysis,11 metabolomics,12 and quantitative analysis.13 These skills are in 
demand in the pharmaceutical industry and future plans include expanding the LC-MS 
component by the incorporating LC-MS/MS analysis into the course. 
HAZARDS AND SAFETY PRECAUTIONS 
Students were given a laboratory safety lesson and a laboratory tour before the first 
experiments were  
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carried out. Eye washes, safety showers, spill kits, and appropriate hazardous waste 
disposal areas  
were identified. Students also researched any toxic substances produced by their 
specimens. 
Supporting Information (Appendix A) 
The Supporting Information is available on the ACS Publications website at DOI: 
10.1021/acs.jchemed.  
Supplemental Figures and Data (DOCX) 
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 Pathogenic bacteria continue to pose threats to human health, and cost billions 
of dollars in healthcare annually. Two of the most common bacterial infections are 
urinary tract infections (UTI) caused by Escherichia coli, and Staphylococcus aureus 
infections. Some strains of S. aureus have become resistant to common antibiotics, and 
there is a critical unmet need for the discovery and development of new drugs. The 
discovery of new small molecules that can eradicate a UTI fully, including cells in a 
quiescent stage is also needed to prevent reoccurring infections. Medicinal plants have 
shown promise as sources of new small molecule therapeutics and supplements. The 
PRISM library, described in the previous chapter, was screened for activity against 
strains of methicillin-resistant S. aureus (MRSA) and uropathogenic E.coli. A 
sesquiterpene lactone (laurenobiolide) from the tulip tree (Liriodendron tulipifera) was 
identified as the active component from the tulip tree extract against S. aureus and a 





 Infections caused by pathogenic bacteria claim millions of lives yearly and accrue 
billions of dollars in healthcare costs.1 The discovery and implementation of antibiotics to 
combat pathogens has saved millions of lives worldwide since the discovery of penicillin 
by Sir Alexander Fleming in 1928.2,3 The penicillin molecule contains a β-lactam ring that 
acts as the warhead killing bacterial cells by inhibiting the formation of cell walls.4 Only 
decades after Fleming first introduced penicillin to the world, the bacteria that were once 
killed by penicillin began to develop resistance to the molecule, and subsequent 
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antibiotics such as methicillin, which also contains a β-lactam ring. Apart from β-lactam 
antibiotics, various other classes of antibiotic molecules that have unique mechanisms of 
action such as inhibiting protein biosynthesis, inhibiting DNA synthesis, or inhibiting 
metabolism of folic acid have been discovered and utilized in the clinic.4 However, 
bacterial resistance continues to develop to new chemical entities.  
 One persistent pathogen is methicillin-resistant Staphylococcus aureus (MRSA). 
MRSA is an economically important pathogen associated with morbidity, mortality, and 
extended hospital stays. MRSA can infect multiple human organs, but the skin is the 
most common. Untreated MRSA infections can lead to invasive infections that lead to life 
threatening conditions such as endocarditis.5 Cases of endocarditis are increasingly 
prevalent in illicit drug users from actions associated with injection drug use such as 
failure to clean needles or hands before use.6  
 Beyond developing resistance to antibiotics, some bacteria develop alternative 
ways to persist despite the introduction of drugs designed to eradicate them. One 
persistent pathogen is uropathogenic Escherichia coli (UPEC). UPEC infections are the 
most common type of bacterial infection and are responsible for 65-90% of UTIs.7 In the 
United States alone, this accounts for nearly $5 billion dollars in healthcare costs 
annually.8 Even after the UTI is initially treated, 20-30% of adult women will have a 
recurring UTI emerge within 4 months.9 Interestingly, in 77% of UTIs, it is the original 
bacterial strain that is responsible for the recurrence.7 This is possibly due to the E. coli 
developing a biofilm-like intracellular bacterial community (IBC) and quiescent 
intracellular reservoirs.10 These adaptations allow the E. coli to enter a quiescent state 
where the bacteria hide in the epithelium of the bladder, evade antibiotic molecules, and 
then periodically re-emerge and re-colonize to facilitate a UTI.11 
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 Antibiotic drugs typically target components of actively dividing bacteria, allowing 
the E. coli in the quiescent state to avoid eradication.12 Some natural products such as 
components in cranberry (Vaccinium macrocarpon) have shown efficacy in interfering 
with bacterial adherence to bladder cells, which can help reduce E. coli populations in 
cells. A novel assay developed at the University of Rhode Island utilizes glucose minimal 
media paired with low density E. coli on agar plates, allowing the cells to exhibit 
quiescence, but stimulation via small molecules can reverse this phase and generate 
observable colonies.7 
 Plant metabolites offer promise in providing new molecular scaffolds to use as 
antibiotics either alone or in combination with previously discovered antibiotics to 
increase the efficacy.13,14 The same metabolites that the plant uses to fight microbes in 
the environment can be harnessed to combat human pathogens.   
 The University of Rhode Island houses a medicinal garden comprised of over 
200 specimens. Recently, we developed a new plant extract library comprised of 
aqueous and organic extracts of aerial and root portions of each specimen from the 
garden.15 The extract library was utilized in anti-bacterial testing using a strain of MRSA 
and uropathogenic E. coli strain.   
  Herein, we identified the methanol extract of the tulip tree (Liriodendron 
tulipifera) as having activity against a MRSA strain. This extract was investigated further 
through bioassay-guided isolation. The active compound was ultimately identified as 
laurenobiolide, a sesquiterpene lactone. We further investigated the relative abundance 
of this compound in the various parts of the plant. Lastly, we determine the safety of this 
compound to human skin cells, as well as the isolated congeners of laurenobiolide - 
tulipinolide and epi-tulipinolide. The methanol extract of saffron (Crocus sativus) was 
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highlighted as one of the many extracts able to reverse E. coli quiescence, which was 
also subjected to bioassay-guided fractionation and isolation.    
 
RESULTS AND DISCUSSION 
 Although numerous plant extracts showed activity in these assays, the plant 
extracts that were prioritized for the S. aureus and UPEC work included plants that had 
been understudied in the literature, and plants with traditional uses relevant to the work 
(e.g. tulip tree and saffron).  
 Liriodendron tulipifera or the tulip tree, is a large flowering deciduous tree found 
naturally across the eastern side of the United States. Native American tribes used the 
tulip tree for its valuable wood, but medicinally it was utilized as a tonic, antipyretic, and 
it was used to treat malaria.16-18 Early American settlers used this native knowledge and 
utilized the bark of the tulip tree as a replacement for Cinchona bark for anti-malarial 
activity.17 During the Civil war, the botanist and surgeon Francis Porcher was tasked with 
compiling a book containing plant remedies that are native to the Southern States to aid 
in helping soldiers deal with injuries. One of the plants he highlighted in his short book 
was the tulip tree.19,20 As research and development grew and scientists began to study 
traditional medicine, some of the original uses of the tulip tree were validated. Once such 
validation was discovering the anti-plasmodial activity of the aporphine alkaloids and 
sesquiterpene lactones isolated from the tree.21 
 There has been a consistent effort to develop drugs with unique chemical 
structures and mechanisms of action to combat pathogen resistance.22 Compared to the 
other common classes of antibiotics such as β-lactams, cephalosporins, and 
tetracyclines, there are very few anti-bacterial compounds in the terpene class. 
However, terpenes and terpenoids are an incredibly diverse group of phytochemicals 
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that show potential as potent antimicrobials.23 The exact mechanism of action of terpene 
antibiotics is unknown, but Griffin et al. identified that terpene metabolites inhibit two 
essential processes, which include oxygen uptake and oxidative phosphorylation.24 
 Initial screening of the tulip tree methanol extract via antimicrobial disc diffusion 
assay showed moderate activity against methicillin-resistant S. aureus. Upon 
investigation of the metabolite profile via high performance liquid chromatography 
(HPLC) (Figure S1), the complex extract was further fractionated and re-tested in the 
MRSA assay. Five fractions of varying polarity were tested and the most activity was 
observed from fractions 3 and 4 corresponding to a 40% water: 60% methanol fraction, 
and a 20% water: 80% methanol fraction, respectively (Figure 1). Upon visual analysis 
of the HPLC chromatograms for each fraction, the most active fractions contained two 
large peaks eluting at 30 minutes from the column. It was speculated that a compound in 
one of these peaks could be responsible for the observed activity.   
 
F1 1 Figure 1: Antibacterial activity of L. tulipifera chromatography fractions on 
methicillin-resistant S. aureus. Samples were prepared at 1 mg/mL. Zones of inhibition 
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were evaluated after 24 h after incubation at 37°C. Controls were (+) gentamicin sulfate 
and (-) methanol. 
Following this examination, the two prominent peaks were isolated via HPLC and 
retested for MRSA growth inhibition. The later eluting peak exhibited the largest zone of 
inhibition (Figure S2A). The peak purity was checked using a phenyl-hexyl column and it 
was determined that the earlier eluting peak (peak 1) was a single pure compound. 
However, the later eluting peak (peak 2) was two separate compounds (Figure S2B). 
Upon repurification and retesting of the three compounds, it was determined that only 
peak 2.1 had antimicrobial activity. Peaks 1 and 2.2 did not show any observable 
activity. Upon dereplication via 1D and 2D NMR (Figure S3 – S6) and HRESIMS (Figure 
S7) it was determined that the three compounds were isomers. The active peak 2.1 was 
determined to be laurenobiolide by the specific rotation [α]23D 16.8 (c 1.0, EtOH) which 
closely matched the literature value of [α]25D 17.1 (EtOH) for laurenobiolide.25 
Additionally, examination of the 1H NMR spectra of peak 2.1 showed an envelope of 
olefinic protons from δ 4.70 to 5.50 consistent with the original characterization of this 
metabolite,26 and the 1H NMR spectrum clearly showed the presence of conformational 
isomers, a phenomenon previously described for laurenobiolide during NMR analysis. 27 
Examination of 1H NMR spectra identified peak 1 as epi-tulipinolide, and peak 2.2 as 
tulipinolide. Evidence included a multiplet resonance at δ 5.72 in peak 1 corresponding 
to H-8, which was in a cluster of resonances between δ 4.76 and 5.03 in peak 2.2. 
Furthermore, the acetyl methyl groups at δ 2.09 and 2.06 were consistent with those of 
tulipinolide and epi-tulipinolide, respectively as detailed in the original isolation and 
elucidation work as were the olefinic methyl groups.28 Interestingly, among these three 
sesquiterpene lactones that are extremely similar in structure (Figure 2), only 
laurenobiolide displayed antibiotic activity towards S. aureus.  
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F1 2 Figure 2: The active compound was determined to be the sesquiterpene lactone 
laurenobiolide. The other inactive congeners were identified as tulipinolide and epi-
tulipinolide.  
 
 The minimum inhibitory concentration (MIC) for laurenobiolide was determined to 
be 15 µg via broth dilution assay. The tulip tree has documented antimicrobial activity 
but the molecule responsible for the activity had not been identified until now.18 Lastly, 
the three sesquiterpene lactones were evaluated for their cytotoxic effects to human skin 
cells (Figure 3). An IC50 value of 17.4 µM was measured for laurenobiolide, 49 µM for 
epi-tulipinolide, and 65.3 µM for tulipinolide.  Further evaluation via animal studies will be 




F1 3 Figure 3: Cytotoxicity of isolated compounds from the L. tulipifera tree on human 
keratinocyte skin cells (n=3).  
 
  Lastly, we investigated which parts of the tulip tree contained the highest 
concentrations of the active compound. On the day of collection, the plant was not in 
bloom, so the flowers were not evaluated, however, previous analysis does indicate that 
laurenobiolide is present in the flowers (Figure S8). Molecular networking analysis was 
performed to evaluate the remaining parts consisting of the bark, petiole, leaves, and 
branches. Examining HPLC-DAD data, laurenobiolide was most abundant in the 
branches, and it was also present in the leaves and flowers although in smaller quantities. 
Small quantities were observed in the petioles following HPLC-DAD analysis, but the 
active component was not detected from this part following LC-MS/MS analysis. 
Interestingly, laurenobiolide was not detected in the bark in either analytical approach 
(Figure 4). This is consistent with the traditional Native American uses of the branches for 
medicine, and these data will now inform future harvesting of plant parts while provoking 
intriguing questions about the ecological role of this metabolite for the tree.  
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F1 4 Figure 4: Molecular networking analysis of the tulip tree showing the active 
antimicrobial compound laurenobiolide in the branches (green) and the leaves (red). 
This compound was not detected in other parts of the tree such as the petioles (blue) 
and the bark (orange). Cosine scores are shown in blue, and the size of the node is 
relative to the ion count.  
 
 Turning to UPEC, the quiescence reversing activity of 114 plant extracts was next 
evaluated. After the initial testing of the crude extracts, 79 of the 114 (69.3%) showed 
some observable activity and the remaining 35 extracts (30.7%) showed no observable 
activity. Out of the 79 extracts that were active we prioritized pursuing extracts that 1) had 
the largest zone of activation 2) were organic extracts and 3) activity was only observed 
for methanol extracts (aqueous extract was inactive). The reason for prioritizing organic 
extracts stems from previous research with quiescence reversing molecules. We know 
that amino acids such as lysine and methionine have shown activity as well as sugar 
molecules like those in the cranberry plant, which would be extracted in an aqueous 
solvent.7 One extract stood out because of its agricultural and economic impact and that 
was the petal extract of the Crocus sativus plant, or saffron, a plant widely known for its 
medicinal and culinary uses.29 The stigmas of saffron are collected, dried, and sold as the 
world’s most expensive spice, but the remainder of the plant is often discarded as 
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agricultural waste.26 Therefore, observed activity in the petals is desirable because the 
plant is already extensively cultivated and access to biomaterial is widely available.  
 Samples 94-99 (Figure S9) corresponded to the saffron samples, and the 20% 
water: 80% methanol fraction was prioritized for bioassay-guided isolation due to the 
large zone of activation. Time-based fraction collection was used to separate this active 
sample into metabolite pools for retesting (Figure S10). Fraction pool 1 showed the most 
quiescence reversing activity, and a new HPLC method was developed to isolate the 
compounds in pool 1 and retest in the assay (Figure S11). Compounds 4 and 5 showed 
the most activity (Figure S12, but upon dose titration, compound 4 showed the most 
potent activity (Figure S13). Efforts have been made to dereplicate the active compound, 
including fragmentation of the active compound via HRESIMS/MS (Figure S14), in which 
a neutral loss was observed of 162 Da (Figure S15), and the observed M+H was 319. 
These data paired with the 1H NMR spectrum of the active compound (Figure S16) 
indicated the presence of a sugar moiety. Further evaluation using mass spectrometry 
and 2D NMR experiments will be needed for full structure elucidation of this compound.    
 In this report, we have documented for the first time that the natural product 
laurenobiolide possesses potent anti-MRSA activity, which sheds light on the intriguing 
story of the cultural and historical use of tulip tree preparations. Furthermore, we have 
shown the utility of the PRISM library as a source of molecular potential in a variety of 
therapeutic areas. Future research will focus on the mechanism of action of 
laurenobiolide, its ecological role for the tree, and we will continue to elucidate the 
structure of the active quiescent-reversing component and search for other lead 
metabolites with this biological activity. 
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MATERIALS AND METHODS 
General Experimental Procedures. Optical rotations were measured using a Jasco P-
2000 polarimeter. NMR spectra were recorded using a Varian 500 MHz instrument. 
HRESIMS analysis was performed using an AB SCIEX TripleTOF 4600 mass 
spectrometer with Analyst software. MS/MS data were recorded on this same instrument 
using the product ion function. LC-MS/MS was performed using a ThermoFisher LTQ XL 
mass spectrometer with an electrospray ionization (ESI) source. Semi-preparative and 
analytical HPLC was carried out using a Dionex UltiMate 3000 HPLC system equipped 
with a micro vacuum degasser, an autosampler, and a diode-array detector. 
Preparation of plant extracts  
Plant extracts were prepared as previously described.15 Briefly, plants were separated 
into aerial and underground portions, then further divided for extraction in both aqueous 
and organic (methanol) solvents. Each solvent was vacuum filtered to remove 
particulates, then either freeze-dried or evaporated under reduced pressure to remove 
any remaining solvent. Dried product was sub-aliquoted into small vials and 
reconstituted at 10 mg/mL in (CH3)2SO. 
Bacterial strains and cultivation 
The E. coli strain CFT073 was obtained from the laboratory of Dr. Jodi Camberg, from a 
cryogenically preserved frozen stock comprised of a 1:1 combination of LB broth and 
50% glycerol. For E. coli cultivation, both LB broth and LB agar were routinely used. 
Liquid M9 media was used in a method developed by Dr. Paul Cohen and the M9 agar 
plates were prepared with 1.5% noble agar.30 
 In vitro quiescence inhibition assay 
The methods used in the quiescence inhibition assay follow Dr. Paul Cohen’s methods 
as described in Leatham-Jensen et. al. 2016.30 Briefly, cultures of E. coli CFT073 were 
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grown overnight in 0.4% glucose with M9 minimal medium. The E. coli were further 
diluted to a final concentration of 205 CFU in 4 mL of liquid overlay media. 0.2% glucose 
M9 minimal media agar plates were prewarmed and the 4 mL of overlay inoculum was 
poured over the agar then allowed to solidify at room temperature. Plant extracts 
reconstituted at 10 mg/mL were spotted onto the plates with 10 μL of each test solution. 
The E. coli that were not growing were considered to be quiescent if the growth was able 
to be induced by the positive control consisting of 5 μL co-spotted tyrosine, lysine, and 
methionine at 0.1 mg/mL. A positive result was defined in this assay as visually 
observable bacteria growth at the spot of testing after a 24 h incubation. Negative results 
were defined as no observable growth at the test site after 24 h. Images of each agar 
plate were taken using a Molecular Imager Gel Doc XR+ (Bio-rad, Hercules, CA, USA) 
system with Image Lab Software. 
Methicillin-resistant Staphylococcus aureus inhibition assay   
Liquid LB broth (Difco, Fisher scientific, Waltham, MA) was autoclaved in 10 mL aliquots 
in capped culture tubes. Methicillin-resistant Staphylococcus aureus strain DSM 1104 (a 
gift from Dr. David Rowley’s laboratory at URI) was kept in the -80°C freezer until 
inoculation, and then a sterile loop was used to transfer bacteria to growth broth. 
Samples were grown overnight at 37°C. LB agar (Alpha biosciences, Baltimore, MD) 
was autoclaved, and 15 mL was poured into 100 x15 mm petri dishes (Thermo fisher, 
Waltham, Ma). Agar plates were left at room temperature to solidify. After drying, the 
plant extracts were prepared as described above and 20 μL were placed on a sterile 
antimicrobial susceptibility test disc (Oxoid, Thermo Fisher, Franklin, MA), and allowed 
to dry for 30 minutes. The positive control, gentamicin sulfate was prepared at 2 mg/mL 
and 10 μL was added to a disc for each plate. Negative vehicle controls were (CH3)2SO 
or CH3OH (20 μL). 
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Minimum inhibitory concentration (MIC) of tulip compounds  
 The minimum inhibitory concentration of laurenobiolide was evaluated using a 
broth dilution method. The MRSA was grown overnight in a 10 mL culture tube 
consisting of sterile LB broth. A 1:1000 dilution was completed by taking 100 µL of 
culture and placing it into 9.9 mL of fresh LB media and vortexing to mix. This mixture 
was further diluted 1:10 by taking 1 mL of the first dilution into 9 mL of new LB broth. A 
96-well round bottom plate (Corning, Corning, NY) was labeled with samples in triplicate 
with positive and negative controls being gentamicin sulfate and methanol). 195 µL of 
diluted bacteria was pipetted into the first row of the 96-well plate. 100 µL was added to 
each row following. 5 µL of the test samples and controls were added to the first row of 
the corresponding wells. Samples were mixed and serial diluted by taking 100 µL of the 
first row, mixing with 100 µL in the following and continuing until the last row where the 
final 100 µL was discarded. The plate was covered with a breathable cellulose 
membrane and incubated for 24 h. Following incubation, bacterial growth was assessed 
by measuring OD600. 
Bioassay Guided Fractionation of Crude Plant Extracts  
Prioritized extracts were further fractionated to rarify samples before additional testing 
using C18 SPE cartridges (Agilent, Lexington, MA). Five fractions were produced from 
each crude extract, beginning with the most polar (80% H2O: 20% CH3OH) and ending 
with the least polar (100% CH3OH). Following solvent removal, the chromatography 
fractions were reconstituted at 10 mg/mL in mobile phase followed by HPLC analysis. A 
70 min gradient was utilized beginning with 15% acetonitrile (CH3CN) for 10 min, then 
increasing the concentration of CH3CN until 45 min, with a 20 min hold at 100% CH3CN, 
followed by a return to starting conditions for 5 min. The resultant chromatograms were 
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visually evaluated in parallel with repeated antimicrobial assays to identify potential 
active compounds.  
Culturing Human Keratinocytes (HaCaT) 
 Human keratinocytes (HaCaT) were a kind gift from the laboratory of Dr. 
Navindra Seeram at URI, and originally purchased from American Type Cell Culture 
Collection (ATCC, Rockville, USA). The culture was maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) (Life Technologies, Gaithersburg, MD, USA) and the DMEM 
was supplemented with 10% fetal bovine serum (FBS, Life technologies). The incubator 
was kept at 37°C with 5% CO2  at constant humidity. All test samples were dissolved in 
sterile (CH3)2SO  for viability assessments.  
Cytotoxic evaluation of keratinocytes (HaCaT) in the presence of L. tulipera 
compounds 
 The viability of HaCaT cells in the presence of laurenobiolide, tulipinolide, and 
epi-tulipinolide was evaluated using cell titer glo (CTG 2.0). HaCaT cells were seeded in 
a sterile 96-well plate at 5x103 cells per well and incubated for 12 h, which was the time 
necessary for adherence. Following this incubation, media was removed from each well 
and compounds were added along with new media, followed by a 24 h incubation. After 
the allotted time, the CTG 2.0 reagent was added to each well and shaken at 200 rpm 
for 2 min using an orbital shaker. The plate was allowed to equilibrate at room 
temperature for 10 min, and then the luminescence was recorded using a Spectramax 
M2 plate reader.  
Isolation of sesquiterpene lactones from Liriodendron tulipifera  
 Having identified the potential active components in the chromatography 
fractions following initial chromatogram analysis, fractions 3 and 4 were combined and 
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subjected to reversed-phase semi-preparative HPLC using a Kinetex 5 μm C18 column 
(250 x 10 mm) and a gradient method. Mobile phase: 60% CH3CN /40% H2O with 0.05% 
formic acid added to each solvent and flow rate of 3 mL/min. Initial conditions were held 
for 10.5 min followed by a linear gradient to 12 min reaching 100% CH3CN and holding 
at this concentration for 4 min, ultimately returning to initial conditions from min 17-20. 
Two chromatographic peaks were collected at tR 9.5 (peak 1 - epi-tulipinolide) and 10.0 
min (peak 2), respectively. Peak 2 was further purified using a Phenylhexyl 5 μm C18 
column (250 x 10 mm) and an isocratic method. Mobile phase: 55% CH3CN/45% H2O 
with 0.05% formic acid added to each solvent and flow rate of 3 mL/min. Peaks 2.1 
(laurenobiolide; tR 13.5 min) and 2.2 (tulipinolide; tR 14.25 min) were isolated. The 
specific rotation measured [α]23D 16.8 (c 1, EtOH) closely matched the literature value of 
17.1 (c 1, EtOH) for laurenobiolide.31 
Molecular network analysis of L. tulipifera plant parts  
Samples of tulip tree bark (trunk bark), branch, petiole, and leaf were taken from 
the specimen on the URI campus and methanol extracts were made as previously 
described. Each extract was subjected to LC-MS/MS analysis with a specific scan event 
recording MS/MS spectra in data-dependent acquisition mode. A Kinetex 5 μm C18 
column (150 x 4.6 mm) was used for separation of analytes in the extracts. The LC 
method consisted of a linear gradient from 15% to 100% CH3CN in H2O + 0.1% formic 
acid over 20 min, followed by an isocratic period at 100% CH3CN of 5 min. The flow rate 
was held constant at 0.4 mL/min. The MS spray voltage was 3.5 kV with a capillary 
temperature of 325 °C. For the MS/MS component, the CID isolation width was 1.0 and 
the collision energy was 35.0 eV. Following acquisition, the raw data files were 
converted to mzXML format using MSConvert from the ProteoWizard suite 
(http://proteowizard.sourceforge.net/tools.shtml). The molecular network was generated 
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using the online platform at Global Natural Products Social Molecular Networking 
website (gnps.ucsd.edu). A network was then created where edges were filtered to have 
a cosine score above 0.7 and 6 matched peaks. The network was visualized using the 
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ABSTRACT  
Metabolite mining of environmentally collected aquatic and marine microbiomes offers a 
platform for the discovery of new therapeutic lead molecules. Combining a pre-
fractionated chromatography library with LC-MS/MS-based molecular networking, and 
biological assays, we isolated and characterized two new micropeptins (1 and 2) along 
with the previously characterized micropeptin 996. These metabolites showed potency in 
anti-neuroinflammatory assays using BV-2 mouse microglial cells, showing 50% reduction 
in inflammation in a range from 1-10 μM. These results show promise for cyanobacterial 
peptides in the therapeutic realm apart from their impact in environmental health and 
provide another example of the utility of large pre-fractionated natural product libraries for 
therapeutic hit and lead identification.  
INTRODUCTION 
 
Neuropathic pain, or nerve pain, resulting from damage to or dysfunction of the 
somatosensory nervous system is notoriously difficult to treat. Neuroinflammation is key 
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in the initiation and persistence of neuropathic pain.1 Recent research has shown that the 
prevalence of neuropathic pain in the United States is approximately 10% of adults, and 
out of those reporting neuropathic pain over 40% were treating with either weak or strong 
opioid drugs.2 This prevalence of neuropathic pain increases in specific cohorts with 33% 
of those with chronic back pain displaying characteristic signs of neuropathic pain.3 
Additionally, chronic, uncontrolled neuroinflammation is an indicative sign of 
neurodegenerative diseases such as Alzheimer’s Disease and Parkinson’s Disease.4,5 
Our group is interested in the discovery of new specialized metabolites from marine and 
aquatic microbiomes that are effective in reducing neuroinflammation. While we have had 
some success in this approach by mining marine cyanobacterial blooms for anti-
neuroinflammatory agents,6 freshwater cyanobacterial blooms offer additional chemical 
space for discovery, especially in terms of cyclic peptides.7 These peptides belong to 
several classes including the microcystins, aeruginosins, microginins, anabaenopeptins, 
micropeptins, microviridins and cyclamides. More than 600 peptides and peptidic 
compounds have been described from various cyanobacterial taxa.7 Many of these 
peptides are hepatotoxic, such as the microcystins, which can cause non-alcoholic liver 
disease and acute liver failure.8,9 Consumption of contaminated drinking water is 
considered the major route of human exposure to microcystins, and the EPA has set 
concentration limits on these toxins (1.6 μg/L = Do Not Drink; 20 μg/L = Do Not Use). 
While neurotoxins and hepatotoxins are a significant public health concern, these blooms 
are comprised of a complex milieu of taxonomically diverse microbes, each possessing 
various biosynthetic capabilities. Large scale biomass sampling from groups like Biosortia 
have revealed freshwater cyanobacterial blooms are more chemically complex than 
previously assumed, and novel molecules with potent biological activities can be isolated 
and characterized.10,11 Work on this ‘metabolite mining’ from complex aquatic microbiomes 
envisions the bloom environment as an ecosystem level complex co-culture experiment 
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in which the aquatic microbiome is producing an equally complex suite of secondary 
metabolites.  
The use of prefractionated natural product libraries has shown promise in increasing 
the potential of identifying lead structures following a bioassay-guided discovery 
approach.12 Biosortia Pharmaceuticals has generated a prefractionated library from 
cyanobacterial biomass dominated by Microcystis aeruginosa originally isolated from a 
wastewater management facility in Muskegon, Michigan. Previous mining of this material 
resulted in the isolation and structure elucidation of new highly cytotoxic microcystin 
toxins.10 A similar workflow was implemented for biomass collected from Grand Lake St. 
Mary’s in Ohio, and this effort resulted in the identification and characterization of the 
exquisitely potent cyanobufalin toxins.11 Each chromatography fraction in the library 
contained a rarefied mixture of chemicals allowing hits to be identified from less complex 
starting material compared to crude extracts or more complex fractions. Pairing the 
prefractionated library with metabolite profiling tools such as LC-MS/MS-based molecular 
networking afforded the opportunity for rapid annotation and dereplication.13 Implementing 
these approaches allowed our group to isolate and characterize two new micropeptins (1 
and 2) and the previously discovered micropeptin 996 (Figures 1 and S1). All three 
metabolites showed potent inhibition of the inflammatory response in BV-2 murine 
microglial cells. 
 
F2 1  Figure 1. Structures of micropeptins 982 (1) and 957 (2). 
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RESULTS AND DISCUSSION 
 
Structure Elucidation of Micropeptin 996, 1 and 2.  
Biosortia’s chromatography fraction library consisted of over 150 individual samples 
each with a rarefied collection of microbial metabolites. Following a bioassay-guided 
isolation approach, we prioritized fractions with low cytotoxicity and strong anti-
inflammatory effects in the BV-2 murine microglial cell line. Fraction D29 showed no 
significant cytotoxicity and inhibited the production of nitric oxide species (NOS) in the 
cells by greater than 50% at a 10 μg/mL dose (Figures S2 and S3).  
 While we were using a pre-fractionated library for screening, the samples were 
still relatively complex, likely due to the complex consortia of bacteria and other 
microbes in the original biomass. In order to rapidly annotate and visualize the chemical 
space in the fraction of interest (D29), we subjected the fraction to LC-MS/MS analysis 
followed by molecular networking. The resultant network showed five separate clusters 
with clusters 1 and 2 showing 15 and 9 individual nodes, respectively and parent 
masses between m/z 900-1100 (Figure S4). Comparing precursor m/z values and 
previous molecular networks available in the literature, we putatively identified the 
metabolites in clusters 1 and 2 as micropeptins or cyanopeptolins.14,15 Nodes 1019 and 
1005 showed high ion counts in mass spectrometry analysis and were abundant in the 




F2 2 Figure 2. Molecular networking cluster showing micropeptin 982 (1) and micropeptin 
996 as nodes 1005 (M+Na+) and 1019 (M+Na+), respectively. These nodes are enlarged 
and in yellow. 
 
 Following examination of the molecular networks, additional chromatographic 
procedures and testing led to the isolation of three metabolites (Figures S5 and S6). 1H 
NMR and 13C NMR analysis indicated that these molecules were peptidic in nature and 
that they were closely related to each other in chemical structure (cf. Figures S7, S8, 
S11, S12, and S20).  
 The first metabolite of interest (Fraction D29, peak 7) gave an m/z of 1019.4854 
[M+Na]+ following HRESIMS analysis suggesting a molecular formula of C52H68N8O12 
(Figure S9). Dereplication efforts based on mass spectrometry data (Figures S9 and 
S10) identified micropeptin 996 as the likely metabolite and further examination of 1H 
NMR and 13C NMR spectra confirmed the identification as these data matched the 
previously published data exactly.16  
 The second metabolite (1) (Fraction D29, peak 6.1) gave an m/z of 1005.4698 
[M+Na]+ following HRESIMS analysis suggesting a molecular formula of C51H66N8O12  
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and 23 degrees of unsaturation (Figure S18). Dereplication efforts did not readily identify 
a known micropeptin with this m/z value. The molecule was 14 Da less than micropeptin 
996 and the 1H NMR and 13C NMR spectra of 1 and micropeptin 996 were nearly 
identical and the presumption was a difference of a CH2 group between the two 
compounds. Examination of 2D NMR data including HSQC, HMBC, COSY, TOCSY, and 
NOESY spectra (Table 1 and Figures S1 and S13-S17) established spin systems and 
connections for the following sequence of amino acids: valine, N-methyl phenylalanine, 
phenylalanine, amino hydroxy piperidone (Ahp), tyrosine, threonine, glutamine, and 
butyric acid. The difference being the substitution of a tyrosine in 1 for the homotyrosine 
in micropeptin 996. The planar structure of 1 was also supported by MS/MS 
fragmentation data, which identified a key fragment (m/z 404.1832) as Ahp-Phe-N-
MePhe-H2O (Figure S19).16 The relative configuration of the Ahp residue was assigned 
based on NOE correlations between H-2Ahp, H-4aAhp, and H-5Ahp showing that these 
hydrogens were co-planar. Additionally, the NH proton of the Ahp residue showed an 
NOE correlation to H-3aAhp, which showed an NOE correlation to the OH group attached 
to C-5Ahp (Figure S1). This was consistent with previously published research assigning 
the relative configuration of the Ahp residue.16,17 Compound 1 was given the name 
micropeptin 982, which is a general convention to designate these micropeptins by 
molecular weight.  









 The third metabolite (2) (Fraction D29, peak 6.2) gave an m/z of 980.4858 
[M+Na]+ suggesting a molecular formula of C49H67N9O11 and 21 degrees of unsaturation 
(Figure S24). Examination of the 1H NMR spectrum showed additional resonances in 2 
in the region from 7.0 to 7.5 ppm and two shielded doublets (δH 0.88 and 0.75) that were 
not present in 1 (Figure S20). Examination of the 1H NMR spectrum and 1H-1H 2D NMR 
spectra (COSY, TOCSY, NOESY, Figures S21-S23) established spin systems 
consistent with the following amino acids: valine, N-methyltryptophan, phenylalanine, 
amino hydroxy piperidone (Ahp), valine, threonine, glutamine, and butyric acid. The 
sequence of amino acids was established via NOE correlations, MS/MS data, and 
analogy to previously characterized micropeptins. An NOE correlation between Ahp-OH 
(δH 5.85) and H-9 of Phe (δH 6.78) supported that these residues were connected. The 
MS/MS data showed a fragment m/z 443.1931, which supported the fragmentation of 
Ahp-Phe-N-MeTrp-H2O (Figure S25). This left two positions in the peptide ring to be 
occupied by valines along with ester formation by threonine and the Gln-BTA side chain. 
The relative configuration of the Ahp residue was identical to that of 1 based on NOE 
correlations and 2 was given the name micropeptin 957.      
 The absolute configuration of the amino acids in 1 and 2 was determined by acid 
hydrolysis of both compounds. Next, we treated the hydrolysates with Marfey’s reagent 
(L-FDAA) to generate derivatives, and finally we completed chromatographic 
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comparison of the derivatized hydrolysates to authentic L- and D-amino acid standards 
(Figures S26 and S27). All amino acids in both 1 and 2 matched L standards and the 
configuration of the Ahp residues in both compounds is proposed based on relative 
configuration and comparison to previously characterized micropeptins. 
Biological Activity. Each micropeptin tested (1, 2, and micropeptin 996) showed the 
ability to reduce NOS in BV-2 microglial cells following stimulation with bacterial LPS 
(Figure 3). Approximately a 50% reduction in NOS was observed for doses of each 
metabolite at 10 μM, and significant reduction in NOS was shown at concentrations as 
low as 0.1 μM. We tested each metabolite for the ability to inhibit the protease plasmin 
with the rationale that perhaps the anti-inflammatory activity was the result of the 
inhibition of this protease in the cell. The activation of plasminogen to the protease 
plasmin occurs in cellular inflammatory responses and plasminogen activation has 
shown the ability to activate microglial cells.18,19 Additionally, other micropeptins have 
shown the ability to inhibit plasmin.20 However, in vitro enzyme inhibition assays did not 
show inhibition when concentrations of the micropeptins were tested up to 10 μM 
concentrations (Figure S28). 
 In this report, we have isolated and characterized two new micropeptins (1 and 
2), and we have evaluated the ability of three micropeptins (1, 2, micropeptin 996) to 
reduce inflammation in BV-2 microglial cells. Micropeptins are a large class of 
cyanobacterial peptides with over 82 variants,7 and a complicated nomenclature which 
includes alternative names to micropeptin such as cyanopeptolin, aeruginopeptin, 
anabaenopeptilide, oscillapeptilide, oscillapeptin among several others.7 However, 
despite the many names, the chemistry is more consistent in this group as the class is 
characterized by the 3-amino-6-hydroxy-2-piperidone (Ahp) residue and an ester linkage 
formed by the β-hydroxy group of threonine and the carboxy group of the terminal amino 
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acid. There are four other ring amino acids (six total), which can be variable and the 
penultimate residue (from the point of view of biosynthesis) is N-methylated. There are 
two additional residues not in the ring: one an amino acid and the other a fatty acid. 
These characteristics are also observed in 1 and 2. Intriguingly, while these metabolites 
are generally thought to be sequestered to cyanobacterial metabolism, a recent 
cyanopeptolin isolated from a Streptomyces olivochromogenes strain provokes thoughts 
as to the evolutionary history of this class of molecules.21 A consistent biological activity 
observed in this class is protease inhibition in contrast to the phosphatase inhibition 
observed from microcystins.22 For instance, micropeptin 996 was previously shown as a 
potent inhibitor of chymotrypsin with an IC50 of 0.64 μM.16 Micropeptin T2 showed potent 
inhibition of plasmin (IC50 = 0.1 μg/mL), while micropeptin T1 showed no ability to inhibit 
this protease (IC50 > 100 μg/mL).20 The difference between the two metabolites was a 
substitution of lysine in T2 instead of the tyrosine in T1 (in the same amino acid position 
as tyrosine in 1). We observed no plasmin inhibition from 1, 2, or micropeptin 996 and 
this may be due to specific amino acid residues conferring this activity to specific 
micropeptins. Additional structure-activity relationship studies should prove illuminating 
with respect to protease inhibition. Other micropeptins such as kyanamide, symplostatin 
5, and tutuilamides A-C all showed potent inhibition of elastase.17,23,24 
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F2 3 Figure 3. Anti-inflammatory activity of micropeptin 982 (MP 982) 1, micropeptin 957 
(MP 957) 2, and micropeptin 996 (MP 996) tested against BV-2 murine microglial cells. 
All data is expressed as mean ± standard error (n = 3), and the significance was 
reported by analysis of variance (ANOVA) followed with Dunnett’s multiple comparison 
procedure. Significance (α = 0.05) as compared with LPS, p ≤ 0.0002 (***) and p ≤ 
0.0001 (****). 
 
Symplostatin 5 additionally alleviated inflammation in an epithelial lung airway model 
system.22 We observed a reduction in inflammation in microglial cells after treatment with 
the micropeptins reported in this study and further explorations of their mechanism of 
action in microglial cells in warranted. For realistic therapeutic development of CNS drugs, 
transport through the blood-brain barrier is essential. While microcystins have been shown 
to rely on transportation through organic anionic transporters (OATs) to move into cells,25 
less is known about the same transport of micropeptins. However, it will be essential to 
determine the ability of micropeptins to cross the BBB to be realistic agents for reducing 
neuroinflammation. In addition to the fraction (D29) that was further mined in this report, 
there are several other fractions of interest that had the ability to reduce NOS levels in 
LPS-stimulated microglial cells (Figure S3). Fraction D29 was chosen for further 
purification because it showed the strongest reduction in NOS when tested at 10 μg/mL 
and also showed no significant cytotoxic effects at the same concentration.  
 
CONCLUSION 
The metabolite profiling approach (LC-MS/MS molecular networking) was implemented in 
our workflow and we quickly identified the micropeptin class in our active fraction. This 
mass spectrometry-guided approach can be paired with bioassay data to identify likely 
bioactive molecules in samples with many analytes.26 Molecular networking has been 
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used to describe the chemical space in cyanobacterial harmful algal blooms,27,28 and 
innovative approaches using this technology will continue to increase the efficiency of 
therapeutic discovery efforts. There are many other likely micropeptins in this active 
sample (Figure S4), and further isolations will allow for structure-activity relationship 
studies to be carried out. There were clearly potent cytotoxins as well in the prefractionated 
library, which may be of interest as potential chemotherapeutics or may be explored for 
their environmental toxicity (Figure S2). High content and information-rich mass 
spectrometry workflows paired with additional bioassays will be necessary to fully exploit 
the potential of the wealth of metabolites in the prefractionated library.  
 
MATERIALS AND METHODS 
General Experimental Procedures. Optical rotations were acquired using a Jasco P-
2000 polarimeter. UV spectra were measured using a Beckman Coulter DU-800 
spectrophotometer. NMR spectra were recorded using a Varian 500 MHz instrument. The 
chemical shifts reported for 1, 2, and micropeptin 996 were referenced to the residual 
solvent peaks of DMSO-d6 (δH 2.50 and δC 39.5). HRESIMS analysis was performed using 
an AB SCIEX TripleTOF 4600 mass spectrometer with Analyst software. MS/MS data 
were recorded on this same instrument using the product ion function. LC-MS/MS was 
performed using a ThermoFisher LTQ XL mass spectrometer with an electrospray 
ionization (ESI) source. Semi-preparative and analytical HPLC was carried out using a 
Dionex UltiMate 3000 HPLC system equipped with a micro vacuum degasser, an 
autosampler, and a diode-array detector. 
 
Collection and Processing of Cyanobacterial Biomass into Prefraction Library. 
Biomass was collected from a holding lagoon at the Muskegon County Wastewater 
Management facility on Maple Island Road, Muskegon, Michigan, USA and concentration 
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of biomass was completed as previously described.10 The biomass was lyophilized and 
sent to AnalytiCon Discovery (Potsdam, Germany) for library fractionation. 10 kg of 
lyophilized biomass powder was repeatedly extracted methanol, and separation over HP-
20 eluting in 10% MeOH steps resulted in a medium polarity fraction. Next preparative 
HPLC generated the pre-fractionated library, which was partitioned into deep well plates 
for initial biological testing.  
 
LC-MS/MS-Based Molecular Networking. Fraction D29 was subjected to LC-MS/MS 
analysis with a specific scan event recording MS/MS spectra in data-dependent 
acquisition mode on a ThermoFisher LTQ XL mass spectrometer with an electrospray 
ionization (ESI) source coupled to a Dionex UltiMate 3000 HPLC system equipped with a 
micro vacuum degasser, an autosampler, and a diode-array detector. A Kinetex 5 μm C18 
column (150 x 4.6 mm) was used for separation of analytes. The LC method consisted of 
a linear gradient from 15% to 100% CH3CN in water + 0.1% formic acid over 20 min, 
followed by an isocratic period at 100% CH3CN of 5 min. The flow rate was held constant 
at 0.4 mL/min. The MS spray voltage was 3.5 kV with a capillary temperature of 325 °C. 
For the MS/MS component, the CID isolation width was 1.0 and the collision energy was 
35.0 eV. The raw data files were converted to mzXML format using MSConvert from the 
ProteoWizard suite (http://proteowizard.sourceforge.net/tools.shtml). The molecular 
network was generated using the online platform at Global Natural Products Social 
Molecular Networking website (gnps.ucsd.edu) [27]. The data were processed by 
removing all MS/MS fragment ions within +/- 17 Da of the precursor m/z. MS/MS spectra 
were filtered by choosing only the top 6 fragment ions in the +/- 50 Da window throughout 
the spectrum. The precursor ion mass tolerance was set to 2.0 Da with a MS/MS fragment 
ion tolerance of 0.5 Da. A network was then created where edges were filtered to have a 
cosine score above 0.6 and more than 2 matched peaks. The spectra in the network were 
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then searched against GNPS' spectral libraries. The library spectra were filtered in the 
same manner as the input data. All matches kept between network spectra and library 
spectra were required to have a score above 0.6 and at least 2 matched peaks. The 
network was visualized using the Browser Network Visualizer tool available on the gnps 
website,29 and then imported into the program Cytoscape for additional analysis. 
 
Isolation of 1 and 2. Fraction D29 from the prefractionated library was subjected to 
reversed phase semi-preparative HPLC using a Kinetex 5 μm C18 column (250 x 10 mm) 
and an isocratic method. Mobile phase: 65% CH3CN/35% H2O with 0.05% formic acid 
added to each solvent and flow rate of 3 mL/min. Seven HPLC peaks (1-7) were collected 
and subjected to the anti-inflammatory assay and an evaluation of purity using 1H NMR 
and LC-MS. This first purification resulted in the isolation of 14 mg of micropeptin 996 (tR, 
26.5 min, peak 7). Peak 6 (tR, 25 min) was further purified using a YMC 5 μm Chiral ART 
Cellulose-SB column (250 x 4.6 mm) using an isocratic method. Mobile phase: 65% 
CH3CN/35% H2O with 0.05% formic acid added to each solvent and flow rate of 1 mL/min. 
Final purification resulted in the isolation of 12 mg of 1 (tR, 5.25 min, peak 6.1) and 2 mg 
of 2 (tR, 10.75 min, peak 6.2).  
 
 Micropeptin 982 (1): colorless oil; [α]23D -65 (c 0.1, MeOH); UV (MeOH) λmax (log ε) 
228  (4.8), 278 (4.1) nm; 1H NMR (500 MHz, DMSO-d6), and 13C NMR (125 MHz, 
DMSO- d6), see Table 1; HRESIMS m/z 1005.4698 [M+Na]+ (calcd for 
C51H66N8O12Na,  1005.4698). 
 
 Micropeptin 957 (2): colorless oil; [α]23D -23 (c 0.1, MeOH); UV (MeOH) λmax (log ε) 
224  (4.8), 274 (3.9) nm; 1H NMR (500 MHz, DMSO-d6), see Table S1; HRESIMS m/z 
 980.4858 [M+Na]+ (calcd for C49H67N9O11Na, 980.4858). 
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Marfey’s Analysis. To determine the absolute configuration of the α-amino acids in 1 and 
2, 0.5 mg of each compound was reconstituted in 0.5 mL of 6 N HCl and heated at 110 °C 
for 15 h. The hydrolysate was dried, reconstituted in 300 µL of 1 M NaHCO3 solution, and 
treated with 50 µL of 1 mg/ml solution of N-α-(2,4-dinitro-5-fluorophenyl)-L-alanine amide 
(L-FDAA) in acetone, followed by heating at 40 °C for 1 h. Next the mixture was cooled to 
room temperature and quenched with 100 µL of 1 N HCl. The hydrolysate was dried and 
reconstituted in 200 µL of CH3CN and filtered through a 0.2 µm filter. The hydrolysate and 
the L-FDAA derivatized α-amino acid standards were subjected to HPLC analysis (20% 
H2O/CH3CN + 0.1% FA to 50% H2O/ CH3CN + 0.1% FA over 30 min and then back to 
initial conditions from 31-36 min; Kinetex C18 column, 150 × 4.6 mm, flow rate 0.6 
mL/min). The retention time (min) of the hydrolysate of 1 matched L-Val (20.4; D-Val, 23.1), 
L-N-MePhe (23.6; D-N-MePhe, 23.9), L-Phe (23.3; D-Phe, 25.1), L-Tyr (18.4, D-Tyr, 19.6), 
L-Thr (12.5; D-Thr, 15.3; L-allo-Thr, 12.7; D-allo-Thr, 13.8), and L-Gln (11.6; D-Gln, 12.0). 
The retention times (min) of the hydrolysate of 2 matched L-Val (20.4; D-Val, 23.1), L-N-
MeTrp (21.6; D-N-MeTrp, 22.4), L-Phe (23.3; D-Phe, 25.1), L-Thr (12.5; D-Tyr, 15.3; L-allo-
Thr, 12.7; D-allo-Thr, 13.8), and L-Gln (11.6; D-Gln, 12.0). 
 
Biological Assays. BV-2 murine microglial cells were cultured as previously described.6 
The cytotoxicity of the library fractions and pure compounds to the cells was measured 
using the CellTiter-Glo® Luminescent Cell Viability Assay (CTG, Promega, Fitchburg, WI). 
BV-2 cells were treated with trypsin and seeded in a white-walled 96-well plate (Corning, 
Corning, NY) at 100,000 cells/mL in DMEM/F-12 media. Cells were allowed to adhere for 
24 h in the incubator followed by treatment with the fractions at 10 μg/mL concentrations 
and eventually pure compounds at final concentrations of 10 µM, 1 µM, and 0.1 µM. After 
dosing, the cells were incubated with fractions or pure compounds for 24 h. Following 
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incubation, the cell viability was measured following manufacturer’s protocols. The CTG 
buffer and substrate were combined, and 100 μL of mixed reagent was added to each well 
followed by two minutes of slow shaking on an orbital shaker, then 10 minutes of non-
shaking equilibration time. The luminescence was measured using a SpectraMax M2 
Plate Reader. Cell viability was then reported as a percent of vehicle control (DMSO). In 
order to test for anti-inflammatory activity, the Griess assay was used. The Griess assay 
reagent kit was purchased from Promega Corp (Fitchburg, WI, USA). BV-2 cells were 
plated in a 24-well plate at 100,000 cells/mL in complete media. Cells were treated with 
fractions or pure compounds for 1 h at the same concentrations used for the cell viability 
assays. After incubation, BV-2 microglia were exposed to (LPS) at 1 µg/mL for 23 h. After 
incubation, 50 µL aliquots were taken from each well and transferred to a clear 96-well 
plate where Griess reagents were added for total nitric oxide concentration determination 
compared to the control wells of DMSO. Statistical significance was determined using a 
One-way ANOVA followed by a Dunnett’s post hoc test, and analysis was performed using 
the program Prism (San Diego, CA). 
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ABSTRACT:  
To combat the bottlenecks in drug discovery and development, a pipeline to identify 
neuropharmacological candidates using in silico, in vitro, and receptor specific assays 
was devised. The focus of this pipeline was to identify metabolites with the ability to 
reduce neuroinflammation, due to the implications that chronic neuroinflammation has in 
chronic pain and neurodegenerative diseases. A library of pure compounds isolated from 
the cyanobacterium Trichodesmium thiebautii was evaluated using this method. In silico 
analysis of drug likelihood and in vitro permeability analysis using the parallel artificial 
membrane permeability assay (PAMPA) highlighted multiple metabolites of interest from 
the library. Murine BV-2 microglia were used in conjunction with the Griess assay to 
determine if metabolites could reduce lipopolysaccharide-induced neuroinflammation 
followed by analysis of pro-inflammatory cytokine concentrations in the supernatant of 
the treated cell cultures. The nontoxic metabolite unnarmicin D was further evaluated 
due to its moderate permeability in the PAMPA assay, promising ADME data, 
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modulation of all cytokines tested, and prediction as an opioid receptor ligand. Molecular 
modeling of unnarmicin D to the mu and delta opioid receptors showed strong theoretical 
binding potential to the mu opioid receptor. In vitro binding assays validated this pipeline 
showing low micromolar binding affinity for the mu opioid receptor launching the 
potential for further analysis of unnarmicin D derivatives for the treatment of pain and 
neuroinflammation related diseases.   
Keywords: neuroinflammation, mu opioid receptor, delta opioid receptor, modeling 
INTRODUCTION  
 The human brain has evolved in the presence of natural sources of CNS-
stimulating molecules for millennia. From the discovery of neuroactive alkaloids in the 
Papaver somniferum plant in 3500 BCE, to more recent discoveries of the first marine 
derived delta opioid agonists there is bountiful evidence that organisms produce 
metabolites that are capable of binding to the receptors in the human brain.1,2 Recently, 
cyanobacterial secondary metabolites have been showcased for their 
neuropharmacological potential.3 Our laboratory has isolated a panel of new-to-science 
metabolites from a Trichodesmium thiebautii bloom, some with moderate cytotoxicity to 
human neuronal cells, but otherwise undetermined bioactivity.4–6 Harnessing the unique 
chemistry of nature for the development of pharmaceutical drugs that target brain 
diseases is an ongoing interest to natural product chemists, but a challenging endeavor 
in drug discovery.  
 It is critical to continue developing neuropharmacological drugs due to the 
increasing prevalence of neurodegenerative diseases in recent decades and the 
prediction that numbers will continue to rise in the future, with little known treatment 
options for these diseases. The risk of developing a neurodegenerative disease 
increases with age; an assessment of people with Alzheimer’s disease (AD) in 2016 
69 
determined that out of the 5.4 million patients who had AD, 5.2 million were over the age 
of 65.7 Due to recent medical advances, humans are living longer than ever and 
neurodegenerative diseases are undoubtedly going to have significant health and 
economic impacts on the US healthcare system.8 
 Chronic, uncontrolled neuroinflammation is a main driver in the development 
neurodegenerative diseases such as AD and Parkinson’s Disease.9,10  Prolonged 
exposure to opioid drugs can also induce inflammation in the brain and increase the 
production of pro-inflammatory cytokines within the neuroaxis.11 These pro-inflammatory 
elements such as IL-1β, TNFα, and IL-6 are found in elevated levels in patients who 
suffer from chronic pain. The treatment of chronic pain with opioids can be detrimental to 
the integrity and stability of neuronal and mental health and heighten the risk of 
developing a neurodegenerative disease in the future.12 In the face of the current opioid 
epidemic, it is uncertain what the long-term side effects will arise for the cohort of people 
affected by the addictive nature of these drugs.  Focusing drug development pipelines at 
reducing inflammation in the brain will result in both acute and long-term benefits for 
patients.  
 Current opioid analgesics have rapid permeation through the blood brain barrier 
(BBB) as well as nanomolar binding affinity to the mu opioid receptor, they are often 
abused and consumed in ways that proliferate their addictive qualities.13 The detrimental 
side effects of these drugs provide rationale for the development of drugs that target 
other receptors involved in nociception such as the delta opioid receptor, or partial 
agonist/antagonist drugs that interact with multiple receptors for the treatment of pain. 
The idea of slowing pharmacokinetics can be a beneficial approach in separating the 
positive response associated with taking a drug, which can lead to downstream 
decreases in addiction rates.14   
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 Agonism of the mu opioid receptor often results in activation of the central 
dopamine reward pathways resulting in a euphoric response and increase in addiction 
potential.15 Apart from the mu opioid receptor (µ, MOR) there are three other known 
opioid receptors in the human brain: the delta opioid receptor (δ, DOR), the kappa opioid 
receptor (κ, KOR), and the nociceptin receptor (NOR). The majority of current and past 
analgesic drugs such as morphine and oxycodone target the mu opioid receptor and 
subsequently the MOR is also the most heavily researched opioid receptor.16,17 Recent 
research has focused on other opioid receptors such as the DOR as a new drug target, 
due to its ability to induce nociceptive pathways and the lessened potential for addiction 
compared to the MOR.18 Further, the polypharmacological activity of compounds 
interacting with multiple opioid receptors is of emerging interest for the treatment of pain.  
A notable example is the bifunctional peptide biphalin, which shows high affinity binding 
to both the MOR and the DOR and produces potent analgesic activity with less 
dependence compared to other opioids.19,20 This bifunctional interaction has been 
investigated, using mainly synthetic molecules, in other MOR/DOR combinations, 
MOR/NOR combinations, and MOR/KOR combinations.21-23 Additionally, mitragynine 
analogs have shown promise as analgesics with a mechanism of action of MOR 
agonism and DOR antagonism.24 These analogs did not recruit β-arrestin-2 following 
receptor binding, which limits tolerance and dependence.24 
 There is an immense need for new analgesic drugs, and drugs that reduce 
neuroinflammation. Due to the plethora of obstacles associated with developing a 
candidate drug for neurodegenerative diseases, discovery and development rates are 
low. Approval rates for central nervous system (CNS) drugs are about half compared to 
non-CNS drugs and marketing approval takes over 30% longer for CNS drugs.25 Oral 
administration of drugs leads to greater compliance in patients compared to other 
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methods of administration.26,27 However, formulation of oral drugs that can subsequently 
cross the BBB after entering the blood stream is difficult to test in early stage 
development of pharmaceuticals.  Additionally, many drugs are subsequently 
metabolized by enzymes after ingestion or are flushed out of the brain via efflux 
transporters. To save time and money there needs to be a method for identifying 
potential CNS drug candidates early in the discovery process that are permeable, safe, 
and efficacious.  
 Herein, we propose a pipeline using in silico and in vitro methods for screening a 
pure compound library comprised of cyanobacterial secondary metabolites from 
Trichodesmium thiebautii.28 Compounds were first screened for their drug-likelihood using 
the online platforms SWISS ADME, and SWISS target predictor.29,30 Each compound was 
then tested for in vitro permeability analysis through an artificial BBB using the parallel 
artificial membrane permeability assay (PAMPA).31 Permeable compounds were further 
investigated for cytotoxicity in murine BV-2 cells, and their ability to reduce LPS induced 
neuroinflammation through the Griess assay. The inflammatory response of the LPS-
induced microglia was further analyzed by investigating various pro-inflammatory 
cytokines via enzyme-linked immunosorbent assay (ELISA). Compounds predicted to 
cross the BBB, exhibited promising ADME, and reduced inflammatory biomarkers were 
further evaluated using molecular modeling to the SWISS predicted candidate protein 
targets.  
  Lastly, metabolite(s) that showed promise throughout these screening 
techniques were evaluated for binding affinity in receptor specific assays. Using this 
approach, we have identified the metabolite unnarmicin D as an opioid receptor ligand 
with affinity for both the mu opioid receptor (MOR) and the delta opioid receptor. 
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Unnarmicin D also produced significant anti-inflammatory activity in cell-based assays 
furthering the therapeutic potential in inflammatory diseases.  
RESULTS AND DISCUSSION 
 
In Silico Analysis of the Cyanobacterial Pure Compound Library. The pure 
compound library of cyanobacterial metabolites (Figure 1, Table S1) was first subjected 
to in silico evaluation based on the physiochemical attributes the metabolites possessed 
as an early indication of drug-likelihood. This process included thorough screening of 
metabolites through the platforms SWISS-ADME and SWISS Target Predictor (Table 
S2, Table S3). Various physiochemical parameters were evaluated such as lipophilicity, 
water solubility, and pharmacokinetics. Inhibition of cytochrome enzymes often causes 
adverse effects in vivo and the predicted inhibition of CYP enzymes was a negative 
attribute of the metabolite. Similar investigations have been completed for in silico drug 
likeness for neuropharmacological drugs.32,33 Lipinski, Ghose, Verber, Egan, and 
Muegge have all published parameters or “rules” for drug likelihood, and although this 
was used as a generalization due to the leniency of these rules in regards to natural 
products, violations of these rules were thought to be disadvantageous. The synthetic 
accessibility was measured in the software program on a scale from 1 (easy) to 10 
(difficult). The value is based on the availability of chemical structures from commercial 
vendors with the assumption that more frequently encountered structures are more 
synthetically accessible. Additional components to the synthetic accessibility score are 
size and complexity. If a natural product derived metabolite were to continue down the 
drug development pipeline, it would eventually need to be synthesized to gather enough 
material for animal and human studies. Some parameters that were of particular interest 
were logP and polar surface area (PSA) due to the relationship between permeability 
and these physiochemical parameters. Three metabolites were highlighted during this 
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screening process: GH2I1 (tricholactone), EF1E (trichophycin B), and GH2C1 
(unnarmicin D). Unnarmicin D, which is a peptide molecule, has more than five nitrogen 
and oxygen atoms, which deems this molecule improbable for crossing the BBB 
according to Österberg and colleagues.34 The number of N and O atoms in a molecule is 
used as a proxy for PSA because they are the main hydrogen bond acceptors. However, 
for unnarmicin D and tricholactone (GH2I1), the logP values calculated by these 
platforms fall very close to the optimal logP for CNS penetrable drugs. This logP range 
developed by Hansch and Leo  determined the optimal range to be 1.5 to 2.7; the 
calculated logP values for unnarmicin D and tricholactone were 2.76 and 2.63 
respectively. 35-37 Continuing down the pipeline, the metabolites were analyzed using the 
SWISS target predictor. Human drug targets were improbable for two of the three 
metabolites, but unnarmacin D (GH2C1) showed the highest probability of being a G-
protein coupled receptor ligand (Figure S1) with moderate probability of being both a mu 




F3 1 Figure 1: Sixteen secondary metabolites isolated in our laboratory from a 
Trichodesmium thiebautii collection that were chosen for further analysis detailed in this 
report.  Molecules are designated by their name and laboratory code, e.g. unnarmicin D 
= GH2C1. 
 
Evaluation of In Vitro Permeability of Pure Compounds through the BBB via 
PAMPA. The first in vitro assay employed in this pipeline was the parallel artificial 
membrane permeability assay (PAMPA) to assess the passive transport of metabolites 
through a membrane designed to simulate the BBB. This is often a roadblock in drug 
discovery, although it was hypothesized that most metabolites in this library would pass 
the membrane because they are small lipophilic molecules. Using this method, all 
metabolites showed good to moderate permeability except for the alkyne containing 
metabolite trichotoxin B (D2F1) (Figure 2A). It should be noted that this assay is only 
assessing passive permeability, and in biological systems there are many factors at play 
such as active transporters to bring metabolites into the brain and transporters that efflux 
unwanted xenobiotics from the brain.38 The PAMPA software calculates the -LogPe by 
detecting the unique chromophore of each metabolite in the donor and acceptor wells 
and comparing the intensity to that of the reference plate. To confirm the results from the 
UV PAMPA plate, the chromatography fraction (fraction “G”) from the original 
cyanobacterial extraction (Figure S2) was subjected to PAMPA analysis to determine if 
the compounds that were permeable in their pure form could be detected in a less-
rarefied solution.  Using the fragmentation pattern identified on a HIRES-TOF-MS for 
three metabolites isolated from this fraction (GH2C1, GH2D8, and GH2N1), transitions 
were monitored for each metabolite on a Sciex Qtrap 4500 mass spectrometer (Table 
S4). The permeability was assessed using the area under the curve (AUC) for each 
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peak in the resulting chromatogram. All three samples showed permeability using this 
analysis (Figure 2B). Verapamil was used as the positive control, and theophylline as the 
negative control. For each compound, a reference measurement was taken before the 
PAMPA was run, this value was normalized to 100% and the acceptor plate was 
analyzed via MS to give a percent recovery value using the area under the curve for the 
detected metabolite. The results from the chromatography fraction are consistent with 
the data shown in the UV plate with the pure compounds, providing additional support 
for this method of permeability analysis.  
 
 
F3 2 Figure 2:  A. The permeability of pure compounds isolated from Trichodesmium 
thiebautii were evaluated for their in vitro passive permeability through the BBB. 
Theophylline was used as a poorly permeable control, corticosterone as a moderately 
permeable control, and verapamil HCl as a highly permeable control. B. Fraction G from 
the original fractionation of the cyanobacterial extract was evaluated in the PAMPA 
assay. The AUC of each metabolite in the reference well was normalized to 100%, the 




 It was originally hypothesized that peptide molecules were unable to pass the 
BBB. However, many studies have proven this incorrect with both exogenous and 
endogenous peptides.39-42 However, peptides do contain a high number of amide bonds 
and hydrogen bond acceptors, which are unfavorable for passively crossing the BBB.43 
This combined with the relatively high molecular weight of unnarmicin D for a CNS drug 
(622 Da) could result in reduced transport across the BBB. The lipophilic tail that 
unnarmicin D possesses increases the overall lipophilicity of the molecule and likely 
contributes to its ability to attach to membranes or passively cross them. Furthermore, 
N-methylation, increased ring size, or changes configuration may help increase the 
passive permeability of this metabolite for future studies.44 Peptide transport is not a 
static process across the BBB and can change based on the needs of the CNS and the 
physiochemical environment, which in the case of chronic pain, inflammation, or opioid 
use could be extremely variable between patients.45  
 
Murine BV-2 Cell Analysis of Cytotoxicity and Reduction in Inflammatory 
Biomarkers. Following permeability analysis, compounds were subjected to cell-based 
analysis of toxicity and inflammatory modulation. Murine microglia cells were chosen as 
a model for neuroinflammation due to the presence of opioid receptors and previous 
nociception related studies with this cell line.6 The BV-2 cell viability in the presence of 
the cyanobacterial metabolites was first assessed at concentrations 10 µM, 5 µM, and 1 
µM (Figure S3). Trichophycin B (EF1E) was previously identified as a potential drug 
candidate from ADME screens (Table S2, Table S3), but was too toxic to continue 
testing in downstream assays. All other metabolites were further evaluated for their 
potential to reduce LPS induced neuroinflammation via the Griess assay at 5 µM 




F3 3 Figure 3: Murine microglia (BV-2) cells were pre-treated with cyanobacterial 
metabolites at 5 µM for one hour followed by an LPS-induced inflammation period of 23 
h. Cell culture supernatant was harvested from the treated wells and was used for the 
analysis of A. NOS, B. TNFα, C. IL-6, and D. sTLR-2.  All data is expressed as mean ± 
standard error (n = 3), the significance was reported by analysis of variance (ANOVA) 
followed with Dunnett’s multiple comparison procedure. Significance as compared with 
control DMSO p ≤ 0.03 (#), p ≤ 0.002 (##), p ≤ 0.0002 (###) and p ≤ 0.0001 (####); as 
compared with LPS, p ≤ 0.03 (*), p ≤ 0.002 (**), p ≤ 0.0002 (***) and p ≤ 0.0001 (****). 
 Nitric oxide species (NOS) are gaseous signaling molecules that has been 
shown to influence various neurological factors such as neurotransmitter release, 
synaptic plasticity, neuronal death, and autophagy.47,48 Neuronal damage induced by 
excessive NOS has been hypothesized as a key factor in neurodegenerative diseases 
such as Alzheimer’s Disease, Parkinson’s Disease, and strokes.10,49,50 NOS is highly 
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expressed following activation from various stimuli, including LPS.51 We evaluated the 
potential of the cyanobacterial metabolites to reduce NOS levels following LPS 
activation. Thirteen metabolites were tested at 5 µM and seven were able to significantly 
reduce the NOS levels in the cell culture media (Figure 4A). The metabolite GH2I1, 
which was highlighted as a potential therapeutic metabolite during the ADME screens, 
did not significantly reduce NOS levels. The seven metabolites that significantly lowered 
NOS were further evaluated for their ability to reduce pro-inflammatory cytokines TNF-α 
and IL-6. Multiple metabolites tested significantly reduced the levels of IL-6 (Figure 3B) 
produced by the murine microglia cells, however, only unnarmicin D significantly lowered 
levels of TNF-α (Figure 3C).  Following LPS induced inflammation, unnarmicin D was 
able to significantly increase the levels of soluble TLR2 (sTLR2) (Figure 3D).   
 Toll-like receptors (TLRs) are innate immune receptors in the human body that 
recognize endogenous and exogenous molecular patterns resulting in inflammatory 
signaling.52 In the central nervous system, microglia, astrocytes, neurons, and 
oligodendrocytes are all known to express certain TLRs.53 These receptors are involved 
in a variety of signaling pathways which mediate NOS secretion, and induce the 
expression of inflammatory genes for immune regulation.54 Soluble TLR-2 (sTLR2), has 
been found to suppress TLR-2 mediated inflammation by preventing the binding to other 
co-receptors, resulting in reduced inflammatory response.55,56 After LPS induced 
inflammation, unnarmicin D was able to significantly increase the levels of soluble TLR2 
indicating a downstream decrease in the TLR2 mediated inflammatory response. The 
combination of a decrease in various pro-inflammatory cytokines and an increase in 
sTLR-2 indicates that unnarmicin D has anti-inflammatory potential, as investigated in 
murine microglia. 
79 
 After cytokine analysis, unnarmicin D was highlighted as the lead molecule in this 
study. Therefore, an analog of the molecule was synthesized to produce enough product 
for further downstream analysis (Figures S4-S8). The lipophilic tail of the synthetic 
molecule is two carbons shorter than the organic molecule due to synthetic precursor 
availability. To ensure the activity of the analog was consistent with the natural product, 
the Griess assay was repeated and showed similar anti-inflammatory activity of both 
molecules (Figure S9). The unnarmicin D analog was used for all further receptor 
binding and activity assays. Further, comparing the structure of unnarmicin D with other 
neuroactive peptides such as the endogenous opioid ligand leu-enkephalin (Figure S10) 
provided rationale for hydrolyzing the ester bond to create a linear peptide. However, 
upon base hydrolysis of the ester to obtain the linear molecule (Figures S10-S13), the 
inflammatory response was diminished in comparison to the cyclic product (Figure S9). 
The molecular modeling showed less favorable binding to both the MOR and the DOR, 
significant ligand exposure remained, and predicted binding to the MOR in an allosteric 
site in comparison to the cyclic product, which was predicted to bind in the orthosteric 
binding site (Figure S14). This change may be due to increased flexibility of the linear 
molecule in the binding pocket. 
Molecular Modeling and in silico Analysis of Unnarmicin D and Derivatives  
 Structural analysis of the unnarmicin D analog shows some consistency with 
other known opioid ligands such as morphine, leu-enkephalin, and mitragynine. 
Unnarmicin D already contains a phenolic hydroxyl group (tyrosine) and a benzene 
residue (phenylalanine), consistent with these other active metabolites, but lacks the 
presence of a tertiary amine.57  
 Molecular modeling was performed with the analog using the molecular operating 
environment (MOE) on both the mu opioid receptor (6DDF) and the delta opioid 
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receptors (6PT2) using crystallized structures available in the protein data bank (PDB). 
These receptors were chosen because they were both crystalized with a small peptidic 
agonist. However, upon modeling with the DOR agonist bound receptor 6PT2, a 
significant portion of the ligand was exposed, resulting in poor theoretical binding.  This 
may be due to the conformational change, which occurs after agonist binding, and in 
comparison to the MOR modeling, this receptor does not contain the Gi complex. For 
this reason, modeling calculations were completed for the agonist bound conformation 
(Figure S15A, PDB 6PT2), the antagonist bound conformation (Figure S15B, PDB 
4EJ4), and the non-ligand bound conformation (Figure S15C, 4N6H). 
 Molecular modeling of the unnarmicin D analog in the MOR revealed multiple key 
interactions between the ligand and the receptor, which are critical for opioid activity. 
Shim et al. noted that the most important interaction to predict mu opioid binding is the 
interaction between the Asp147 residue in the binding pocket with a nitrogen on the 
ligand; this interaction plays a direct role in receptor activation and has been validated 
through mutagenesis studies (Figure 4A, Figure 4B).58 Examining the theoretical binding 
in the 3D diagram of the analog (Figure 4A, inset) in the MOR binding pocket, this acidic 
Asp147 residue interacts with three nitrogen atoms, stabilizing the confirmation of the 
ligand in the receptor. Further, the π-π stacking interaction between the aromatic Trp293 
residue and the tyrosine residue of  the unnarmicin D analog increases the likelihood of 
binding (Figure 4B), although this interaction can result in either antagonist or agonistic 
functionality.58 Three of the carbonyls of the peptide’s amide bonds interact with the 
Gln124, His297, and Tyr148 residues in the binding pocket, acting as hydrogen bond 
acceptors, which further adds to the stability of this molecule in this conformation. The 
lipophilic tail and the phenylalanine residue of the analog are exposed in the binding site 
of the MOR as denoted by the blue color around the atoms. This area of ligand exposure 
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with no receptor interactions would likely be the first place to begin an SAR study with 
additional unnarmicin D derivatives. The ligand exposure led to the modeling of an 
unnarmicin D derivative without a lipophilic tail to determine if theoretical binding would 
be increased with less ligand exposure (Figure S16A). A methyl group replaced the 
seven carbon lipophilic tail and the ligands interacted with the receptor in the same 
location as the natural product, however, the aspartic acid residue (Asp147) in the 
binding pocket, which is critical for receptor activation, was now only coordinating with 
one amide nitrogen on the ligand compared to the tri-interaction observed with the  
unnarmicin D analog (cf. Figure 4, Figure S16, and Table S5). Removal of this lipophilic 
portion of the ligand would likely decrease the passive permeability through important 
biological membranes such as the BBB due to decreased lipophilicity.  
 When examining the unnarmicin D analog interaction with DOR, molecular 
modeling to the agonist and antagonist bound DOR receptors resulted in significant 
ligand exposure in the receptor and poor binding constants (Figure S15A-B, Table S5). 
Modeling to the antagonist molecule (Figure S15B) showed no interactions with the 
receptor binding pocket. However, the unbound receptor (PDB 4N6H), displayed 
promising modeling data (Figure S15C). Like the MOR, the DOR modeling with the 
unbound receptor shows a key theoretical receptor-ligand interaction with the Asp95 
residue with an amide nitrogen on the ligand. This interaction is associated with the 
agonist binding domain of the DOR and is necessary for selective agonist binding in this 
receptor.59 Further, this highly conserved polar Asp95 residue has been highlighted by 
multiple studies as one of the positions, which holds the sodium ion in place to facilitate 
protein conformation stability and peptide binding resulting in downstream agonistic 
activity. 58-60 This interaction was observed in our modeling study when water molecules 
were included in the binding predictions for the unbound receptor 4N6H (Figure S17 C 
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and D). Similarly, using the agonist bound receptor (PDB 6TP2) the guanidinium group 
of the Arg 257 residue in the binding pocket of the DOR (Figure S17A) participates in 
hydrogen binding with the carbonyl of a glycine amino acid in the unnarmicin D analog, 
allowing a hydrogen bonding network that extends through intermolecular interactions 
then to the Arg 241 guanidinium group on the other side of the receptor where weak and 
strong hydrogen bonding is predicted. 
 
 
F3 4 Figure 4: Moleular modeling of unnarmicin D in the MOR (6DDF) A.) 3D diagram of 
the ligand in the MOR receptor pocket. B.) A 2D diagram of the ligand-receptor 
interactions.  
 
 Water molecules play an important role in the ligand stabilization and receptor 
activation in many GPCRs.61,62 There are functional restrictions in predicting the role that 
water molecules play during GPCR activation due to water molecule flexibility and 
mobility as well as receptors constantly changing conformation.63  However, modeling 
was performed in the presence of water molecules to determine if theoretical binding 
would significantly change. For both the DOR and the MOR, binding calculations in the 
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presence of water molecules did not significantly enhance binding in probability or the 
strength of the ligand-receptor interaction (Figure S17). 
Receptor-Target Analysis of Unnarmicin D at the Delta and Mu Opioid Receptors.  
Radioligand binding assays of unnarmicin D to the delta opioid and mu opioid receptors 
confirms that this ligand has affinity for both opioid receptors. The percent inhibition of 
the control was used to measure the specific binding. For the delta opioid receptor, the 
DOR specific ligand DPDPE was used as the control and for the mu opioid receptor 
DAMGO was used as the control. Unnarmicin D showed stronger binding affinity to the 
mu opioid receptor compared to the delta opioid receptor with a Ki value of 6.4 µM for 
the MOR (Figure 5A) and a Ki value 21 µM for DOR (Figure 5B, Figures S18-S20). 
Although these data show higher Ki values compared to analgesic drugs currently 
available, these data show promising results for further medicinal chemistry advances on 
this compound. The weak binding potential of the linear molecule predicted by modeling 
was confirmed in the binding assay as this ligand showed no binding ability (Figure S21). 
 
F3 5 Figure 5: Unnarmicin D radioligand binding as percent inhibition of control 
compound. (A.) Unnarmicin D as percent inhibition of the agonist DAMGO at the mu 
opioid receptor. Displaying an in vitro IC50 of 16 μM and a Ki 6.4 μM. (B.) Unnarmicin D 
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as percent inhibition of the agonist DPDPE at the delta opioid receptor. Displaying an in 
vitro IC50 of 38 μM and Ki 21 μM. 
 
CONCLUSION 
 In this report, we demonstrated that the cyanobacterial metabolite unnarmicin D 
is an opioid receptor ligand with affinity for both the mu and delta opioid receptors. 
Furthermore, we have demonstrated that this molecule is non-toxic to murine microglia 
cells and can reduce inflammation in cell-based systems through modification of cell 
signaling molecules nitric oxide, TNFα, IL-6, and sTLR-2. A paradigm shift towards 
focusing drug development to moderate chronic pain that focuses on a reduction in 
neuroinflammation combined with opioid receptor activity could facilitate potential drug 
candidates that can disrupt the cycle of inflammation followed by mood disorders and 
addiction. Further, outside the realm of neuropharmacological drugs, an anti-
inflammatory opioid drug may have implications in inflammatory diseases such as 
Crohn’s Disease and ulcerative colitis, where mu opioid agonists such as the synthetic 
ligand DALDA have shown to be effective in reducing disease flares,64 and the dual 
MOR/DOR agonist biphalin has also showed promise as a new therapeutic.65 These 
data show promising results for further therapeutic development of unnarmicin D. The 
development of an SAR study modifying unnarmicin D with varying amino acids and 
lipophilic substituents to maintain activity but hone in specificity is needed as well as 
testing a panel of receptors to assess the selectivity of unnarmicin D to the remaining 
opioid receptors and other GPCRs, especially KOR and NOR. The utilization of this 
pipeline prioritized compounds with BBB permeability, in vitro therapeutic activity, and 
important potential molecular targets. While we focused on screening metabolites from a 
cyanobacterial collection, the methods proposed here can be utilized for any metabolite 




General Experimental Procedures. NMR spectra were collected using either a Bruker 
800 MHz, Varian 500 MHz, or Bruker 300 MHz instrument. The chemical shifts reported 
were referenced to the residual solvent peaks of either CDCl3, DMSO-d6, and MeOH-d4. 
HRMS analysis was performed using an SCIEX TripleTOF 4600 mass spectrometer with 
Analyst TF software. MS/MS was acquired using a SCIEX Qtrap 4500 coupled to a 
Shimadzu Prominence UFLC system consisting of three LC-20AD pumps, a DGU-20A 
degassing unit, SIL-20AC auto sampler, CTO-20AC column oven and CBM-20A 
communication bus module. Semi-preparative and analytical HPLC was carried out 
using a Dionex UltiMate 3000 HPLC system equipped with a micro vacuum degasser, 
an autosampler, and a diode-array detector.  
 
Biological Material, Collection, and Identification. The pure compound library was 
comprised of cyanobacterial metabolites previously discovered in our laboratory. The 
metabolites were isolated from Trichodesmium thiebautii extracts and verified for purity 
using 1H NMR and HPLC-UV. All metabolites tested showed greater or equal to 95% 
purity except for synthetic unnarmicin D (94%), conulothiazole C (90%) and trichotoxin B 
(87%) (Figures S22-S37).  
 
In Silico Modeling Using SWISS Target Predictor and SWISS ADME. SMILES files 
for each compound were entered into the online platforms SWISS ADME 
(http://www.swissadme.ch/) and SWISS target predictor 
(http://www.swisstargetprediction.ch/) for the prediction of critical physiological 
parameters attributed to drug candidates and drug targets. The full list of compounds 
entered into the spreadsheet with conditional formatting can be found in the 
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supplemental data (Table S1). Lipophilicity was measured using LogP and LogS, as well 
as the program’s algorithms for determining if the candidate molecule would pass the 
BBB and absorb into the human gut. Swiss target predictor was utilized with the 
specifications of Homo sapiens being the target organism for this study. For each 
metabolite screened, the main neuronal receptor target was recorded (Table S2). 
Evaluation of In Vitro Permeability of Pure Compounds through the BBB via 
PAMPA. The quantification of permeability and calculation of -LogPe is performed by 
comparing the UV absorbance of the donor plate where the compound is initially added 
to the UV absorbance of the acceptor well on the other side of the BBB simulation 
membrane and comparing these data to that of the reference plate and blank plate. All 
reagents for PAMPA were purchased from Pion Inc. (Billerica, MA, USA). Prisma HT 
buffer was brought to pH 7.2 using 0.5 M sodium hydroxide. Five µL of 10 mM of each 
pure test compound was diluted in 1 mL of pH adjusted buffer then mixed in the deep 
well plate. Pion BBB lipid matrix was added to the bottom of each filter membrane then 
the diluted compound was added to the donor well of the plate. The acceptor well 
contained BBB acceptor solution. Once the sandwich assay was assembled, the plate 
incubated for four hours in the PION GIT box. Following incubation, all plates were read 
for UV absorbance from 190 nm-800 nm using a SpectraMax M2 multi-mode plate 
reader (Molecular Devices, San Jose,CA).  
Evaluation of In Vitro Permeability of Compounds in a Rarefied Extract through 
the BBB via PAMPA. Chromatography fraction G from the original rarefication of the 
crude cyanobacterial extract was evaluated using PAMPA. The same method was used 
as described above. Following the PAMPA protocol, the plates were evaluated using LC-
MS/MS with MRM on a SCIEX Qtrap 4500 mass spectrometer. The transitions for each 
monitored metabolite were determined utilizing the product ion function of a SCIEX 
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HIRES TripleTOF 4600 mass spectrometer with Analyst TF software. The relative 
quantity of metabolites was measured using the area under the curve (AUC) for each 
metabolite. The closer the AUC of the donor and the acceptor plate shows higher 
permeability.  
Murine BV-2 Microglia General Cell Culture. Murine BV-2 microglia were a kind gift 
from Grace Y. Sun (University of Missouri at Columbia, MO, USA). Cells were 
maintained in 10% heat inactivated FBS, with 1% Penicillin/streptomycin (100 U/mL 
penicillin, 100 mg/mL streptomycin) in high glucose (4.5 g/L) DMEM/F-12 media at 37°C 
with 5% CO2. The cyanobacteria secondary metabolites were reconstituted in sterile 
DMSO to obtain 10 mM stock solutions, then diluted in serum free media to relevant 
concentrations. The control wells were treated with DMSO in serum free media. 
Effects of Cyanobacteria Metabolites on BV-2 Microglia Cell Viability. The 
cytotoxicity of the compounds to murine microglial (BV-2) cells was measured using 
CellTiter-Glo® Luminescent Cell Viability Assay (CTG, Promega, Fitchburg, WI). BV-2 
cells were treated with trypsin and seeded in a white-walled 96-well plate (Corning, 
Corning, NY) at 100,000 cells/mL in DMEM/F-12 media. Cells were allowed to adhere 
for 24 h in the incubator followed by treatment with the cyanobacteria metabolites at 10 
µM, 5 µM, and 1 µM. After dosing, the cells were incubated with the metabolites for 24 h. 
Following incubation, the cell viability was measured following manufacturers protocols. 
The CTG buffer and substrate were combined, and 100 μL of mixed reagent was added 
to each well followed by two minutes of slow shaking on an orbital shaker, then 10 
minutes of non-shaking equilibration time. The luminescence was measured using a 
SpectraMax M2 Plate Reader. Cell viability was then reported as a percent of vehicle 
control (DMSO). 
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Measurement of Nitric Oxide Species (NOS) in Murine BV-2 Cells via Griess Assay. 
The Griess assay reagent kit was purchased from Promega Corp (Fitchburg, WI, USA). 
BV-2 cells were plated in a 24-well plate at 100,000 cells/mL in complete media. Cells 
were treated with cyanobacteria metabolites at 5 µM for 1 h. After incubation, BV-2 
microglia were exposed to (LPS) at 1 µg/mL for 23 h. After incubation, 50 µL aliquots 
were taken from each well and transferred to a clear 96-well plate where Griess 
reagents were added for total nitric oxide concentration determination compared to the 
control wells of DMSO.  
Enzyme-Linked Immunosorbent Assay (ELISA) Analysis of TNFa, IL-6, and sTLR-2 
in Cell Supernatant. Following the Griess assay, the supernatant from cell culture 
experiments was harvested and then frozen to assess cytokine production within 
treatments. Tumor necrosis factor α (TNFα), interleukin-6 (IL-6), and Toll-like receptor 2 
(TLR-2) were evaluated using the ELISA. TNFα and IL-6 ELISA kits were purchased 
from Biolegend (San Diego, Ca, USA) and the TLR-2 ELISA was purchased from Abcam 
(Cambridge, UK). In summary, each plate was coated with primary antibody and kept at 
4°C overnight. The next day the plates were washed followed by a blocking step with 
FBS. The plates were washed again followed by addition of samples and standards. 
After the allotted time, the plates were washed and detection antibody was added, 
followed by a wash step and the addition of HRP solution. Lastly, a final wash was 
completed and TMB substrate was allowed to interact with the HRP in the dark for 15 
minutes. Stop solution was added and the endpoint absorbance was read at 450 nm. 
Synthesis of the Unnarmicin D Analog. The cyclo (R-3-hydroxydecanoyl-Gly-D-Tyr-
Gly-Phe) peptide was synthesized by Peptides International through manual synthesis 
and solution chemistry. The structure was verified by TOF-MS and 1H NMR. Purity was 
determined using HPLC-UV and 1H NMR. Synthetic unnarmicin D analog: 1H NMR (500 
89 
MHz, DMSO-d6) δ 9.21 (1H, s, Tyr-OH), 8.93 (1H, d, J = 5.8 Hz, Tyr-NH), 8.56 (1H, m, 
Gly-2-NH), 7.97 (1H, dd, J = 8.2, 4.8 Hz, Gly-1-NH), 7.39 (1H, d, J = 9.3 Hz, Phe-NH), 
7.22 (2H, m, H-6/8), 7.20 (2H, m, H-5/9), 7.16 (1H, m, H-7), 7.11 (2H, d, J = 8.5, H-
16/20), 6.68 (2H, d, J = 8.5, H-17/19), 5.12 (1H, m, H-25), 4.56 (1H, td, J = 9.5, 5.0 Hz, 
H-2), 4.13 (1H, m, H-13), 3.88 (1H, dd, J = 17.1, 8.2 Hz, H11a); 3.82 (1H, dd, J = 14.7, 
3.8, H-22a), 3.49 (1H, dd, J = 14.7, 6.7, H-22b), 3.36 (1H, dd, J = 17.0, 4.6, H-11b), 3.14 
(1H, m, H-3a), 3.00 (1H, m, H-14a), 2.77 (2H, ovlp, H-3b/14b), 2.58 (1H, dd, J = 13.7, 
3.5, H-24a), 2.17 (1H, dd, J = 13.6, 10.2, H-24b), 1.52 (1H, m, H-26a), 1.44 (1H, m, H-
26b), 1.26 (2H, m, H-31), 1.25-1.22 (6H, ovlp, H-28-30), 1.16 (2H, m, H-27), 0.85 (3H, t, 
J = 7.0, H-32). 
Base Hydrolysis of Unnarmicin D. 0.5 M sodium methoxide was prepared by 
dissolving 27 mg of sodium methoxide power (Fisher Scientific) into a glass vial with 1 
mL of methanol as a diluent. 5 mg of the synthetic unnarmicin D cyclic peptide was 
added to the sodium methoxide solution. A sand bath was brought to 50°C, and the vial 
containing the peptide was placed in the sand bath and stirred for 12 h. The reaction 
was quenched with ca. 2 mL of chromatography grade water and stirred for an additional 
5 min. A partition of DCM and water resulted in 3.2 mg of crude reaction mixture. The 
product was re-isolated on the HPLC using an analytical C18 semi-preparative column 
(Phenomenex) and the following gradient method: 0-5 minutes 40% ACN, 5-13 min 40-
100% ACN, 14-20 minutes 40% ACN (Figure S10). The HPLC product was monitored at 
210 nm, 228 nm, and 254 nm.   
Hydrolyzed synthetic unnarmicin D analog: 1H NMR (500 MHz, MeOH-d4) δ 7.23 (2H, m, 
H-6/8), 7.22 (2H, m, H-5/9), 7.20 (1H, m, H-7), 7.03 (2H, t, J = 8.5 Hz, H-16/20), 6.69 
(2H, d, J = 8.5 Hz, H-17/19), 4.53 (1H, m, H-2), 4.45 (1H, m, H-13), 3.96 (1H, m, H-25), 
3.80 (4H, ovlp, H-11/H-22), 3.20 (1H, m, H-3a), 3.05 (1H, m, H-14a), 2.80 (2H, ovlp, H-
90 
3b/H-14b), 2.35 (2H, m, H-24), 1.48 (2H, m, H-26), 1.24-1.34 (10H, m, H27-H31), 0.89 
(3H, t, J = 7.0 Hz, H-32).  
Molecular Modeling. Molecular Docking. X-ray crystal structures for the mu opioid 
receptor (6DDF, 4DKL)66 and the delta opioid receptor (4N6H, 6PT2, 4EJ4)60 were 
downloaded from the protein data bank (PDB). Molecular docking studies were carried 
out using Molecular Operating Environment.67 All X-ray crystal structures discussed 
were prepared using MOE QuickPrep and receptor-ligand complexes were energy 
minimized prior to Docking. Triangle Matcher was used for the docking placement 
method with London dG for the score at 30 poses. Rigid Receptor was used for the 
docking refinement method with GBCIWSA dG for the score at 5 poses. The SiteFinder 
tool was used to determine statistically relevant binding sites for each ligand in the mu 
and delta opioid receptors. 
MOR and DOR Radioligand Binding Assay. The unnarmicin D synthetic analog was 
tested at several concentrations to determine IC50 and Ki values of the peptide for both 
MOR and DOR by Eurofins Cerep. Compound binding was calculated as a percent 
inhibition of the binding activity of a radioactively labeled ligand specific for each target 
detected by scintillation counting (MOR, DAMGO; DOR, DPDPE). The tests were carried 
out in human recombinant cells (MOR, Chem-1 cells; DOR, HEK-293 cells). Percent 
inhibition of control specific binding was determined for each concentration tested. IC50 
values were determined by non-linear regression analysis of the competition curves 
using Hill equation curve fitting and inhibition constants (Ki) were calculated using the 
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PDB ID Codes 
6DDF: Mu opioid receptor-Gi Protein Complex. DOI: 10.2210/pdb6DDF/pdb 
4DKL: Mu opioid receptor bound to a morphinan antagonist. DOI: 10.2210/pdb4DKL/pdb 
6PT3: Delta opioid receptor in complex with agonist DPI-287. DOI: 
10.2210/pdb6PT3/pdb 
4EJ4: Delta opioid receptor bound to the antagonist naltrindole. DOI: 
10.2210/pdb4EJ4/pdb 
4N6H: Structure of the human delta opioid 7TM receptor. DOI: 10.2210/pdb4N6H/pdb 
5C1M: Mu-opioid receptor bound to the agonist BU72. DOI:10.2210/pdb5C1M/pdb 
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ABSTRACT 
Introduction: Cannabinoids including cannabidiol (CBD) have attracted enormous 
interest as a bioactive ingredient for potential dermatological and/or cosmeceutical 
applications. However, there is a lack of fundamental knowledge on the skin permeability 
of CBD and its topical formulations. Herein, we aimed to evaluate the skin permeability 
of CBD and CBD in a cream formulation using artificial membrane assays.  
Materials and Methods: CBD and its formulations’ skin permeability was assessed 
using artificial membrane-based models including the parallel artificial membrane 
permeability assay (PAMPA) and the Franz cell diffusion (in vitro release testing) assay.  
Results: CBD isolate showed favorable skin permeability in the PAMPA assay (with a -
LogPe value of 5.019 and 5.021, at pH of 6.5 and 7.4, respectively), which was 
supported by data from the Franz cell diffusion assay (51.8 μg CBD released over 8 
hours). In addition, CBD had feasible solubility (378 μg), stability (81% stability at pH 5), 
in the presence of surfactant Tween-20. CBD topical cream formulations also showed 
promising skin permeability in the Franz cell diffusion assay (25.2 μg CBD released over 
8 hours).  
Conclusion: Findings from the current study suggest that CBD is a skin permeable 
cannabinoid, and the permeability of its formulations may be influenced by several 
factors including surfactant, pH environment, and stability.  Further biological evaluations 
using in vivo models are warranted to confirm these activities.  
Keywords: Cannabidiol, skin permeability, PAMPA, Franz cell, cosmetics. 
 
Abbreviations used: 
CBD – Cannabidiol 
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PIB – polyisobutene 
SLS- sodium lauryl sulfate 
(w/w) – weight per weight 
T20 – tween 20 
T80 – tween 80 
 
INTRODUCTION 
 The skin is the largest organ in the human body.1 It is composed of various layers 
of cells that together act as a barrier to keep unwanted biological and chemical 
constituents from permeating and entering the body.2 The avascular outermost layer of 
the skin, called the epidermis, is comprised of keratinocytes, Merkel cells, melanocytes, 
and Langerhans cells, which participate in the protection against inflammation and 
immunological responses.2,3,4 The most superficial layer of the epidermis is the stratum 
corneum, which is the most difficult layer to permeate and is the rate-limiting step in the 
penetration process. Below the epidermis is the vascular dermis layer, which contains 
additional cell types such as fibroblasts but also free nerve endings which play a 
significant role in pain sensation. 2,3 Proper formulations for skin cosmeceutical products 
can result in active ingredient delivery to a specific location such as muscles or blood 
vessels, and transdermal formulations can result in absorption and systemic circulation 
of the active component to achieve prolonged delivery.5 
 Due to the recent legalization and decriminalization status of the medicinal plant 
Cannabis sativa, as well as a general shift towards more natural ingredients in skincare, 
there has been a large increase in the use of Cannabis metabolites in skincare 
products.6 Cannabis sativa is a member of the Cannabaceae plant family. This annual 
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herbaceous plant has many phytochemicals unique to members of this genus, which are 
referred to as phytocannabinoids. The two most abundant phytocannabinoids are 
cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) ( Figure 1).7 THC is 
responsible for the psychoactive effects of the Cannabis plant, whereas CBD is the main 
non-psychoactive cannabinoid.8 The human body also contains endogenous 
cannabinoid molecules, termed endocannabinoids, which are an integral part of the 
endocannabinoid system such as N-arachidonoylethanolamine (anandamide) and 2-
arachidonoylglycerol.9,10 The main molecular targets of the endocannabinoids are the 
cannabinoid receptors 1 and 2 (CB1 and CB2).11 Much of the focus of THC has focused 
on the effects in the central nervous system where CB1 receptors are localized, and 
CBD research has largely focused on the anti-inflammatory effects involving CB2 
receptors located in the peripheral nervous system and immune cells.12 CBD is a weak 
modulator to both cannabinoid receptors but it can modulate the release of 
endocannabinoids, as well as act on additional receptors such as the transient receptor 
potential vanilloid type 1 (TRPV1) and various G-protein coupled receptors.8 The 
location of the cannabinoid receptors within the body ultimately determines the 
physiological reaction. The ECS in the skin is involved in various biological processes 
such as the proliferation, differentiation, and immune tolerance within the various types 
of skin cells.4,13 Every cell type produced by the skin relies on components of the 
endocannabinoid system, this includes the expression of cannabinoid receptors 1 and 2 
on keratinocytes, hair follicles, and sebaceous glands.14,15 Disruption and dysregulation 
in the ECS within the skin cells can lead to skin diseases.16 Other important receptors 
such as the TRPV1 receptor is also highly expressed in epidermal skin cells, which 
facilitates the activity of CBD.17 
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F4 1 Figure 1: The chemical structure of cannabidiol (CBD) (A) and delta-9 
tetrahydrocannabinol (Δ-9 THC) (B) isolated from the plant Cannabis sativa. 
 
 The medicinal benefits of CBD can be enhanced by combining CBD with THC or 
CBD given alone can stimulate the release of the endocannabinoid anandamide by 
inhibiting the FAAH (fatty acid amide hydrolase) enzyme.15 Both the FAAH enzyme, 
which is responsible for degrading and recycling anandamide, and the MAGL 
(monoacylglycerol lipase) enzyme, which is responsible for removing 2-AG are also 
highly expressed in various constituents of the skin.18 Activation of CB1 receptors on the 
skin surface by phytocannabinoids can have therapeutic implications for diseases such 
as psoriasis and eczema due to the role that the endocannabinoid system plays in 
inflammation and immunity.19 Furthermore, cannabidiol has antioxidant properties that 
protect the skin from oxidative stress on the epidermis caused by UVA/UVB radiation 
from the sun. Exposure to UVA and UVB rays shifts redox imbalance towards oxidation 
and ultimately leads to an increase in reactive oxygen species (ROS), which leads to 
cellular damage.20 
 Plant extracts and metabolites have been used for centuries as the active 
ingredient in creams and salves. In the 1880s Dr. Carl Koller found the local anesthetic 
properties of cocaine creams useful for cataract extractions and today various plant 
extracts are incorporated into cosmeceutical formations.21 
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 Recently, CBD has become a popular ingredient in skincare products, asserting 
anti-inflammatory, analgesic, hydration, and other benefits from the incorporation of this 
molecule. With celebrity endorsements, this is projected to become an industry worth 
between $135 and $155 billion (USD) globally by 2021.22 One concern with the 
incorporation of cannabinoids in skincare products is the susceptibility of these 
metabolites to aerobic oxidation, causing a color change from a clear solution to a 
yellowish-brown solution resulting in the formation of hydroxyquinone.23 There remains a 
gap in understanding quantitatively the stability of CBD in solution, as well as the 
permeability of CBD in different skincare formulations. Understanding how to formulate 
skincare products in a way that increases the storage and stability of phytocannabinoids 
as well as increasing the permeation through the skin is critical. Furthermore, it is 
important to determine the rate at which cannabinoids passively diffuse across the skin 
to establish the time that would be required between dosing regimens and identify 
potential targets for skin therapeutics.  A comprehensive understanding of the 
physiology of the skin as well as a physicochemical understanding of the active 
compound is necessary for proper formulation of products to reach the target tissue. The 
stability and permeability of CBD can be investigated using various in vitro assays, and 
this information will further our understanding of this popular cosmetic ingredient for 
future formulation studies and ensure safety and efficacy for product use.  
MATERIALS AND METHODS 
Reagents 
Cannabidiol (CBD; purity 99.46%) was obtained from DB Labs (Las Vegas, NV, USA). 
The cellulose and Strat-M® membranes for Franz cell assay and ethanol were 
purchased from Millipore Sigma (Burlington, MA, USA).  Supor PES membranes, pore 
size 0.1 and 0.45 μM were purchased from Pall Corporation (Port Washington, NY, 
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USA). Phosphate buffer saline was purchased from Sigma-Aldrich Co. (St. Louis, MO, 
USA).  All materials for PAMPA were purchased from Pion, Inc. (Billerica, MA, USA). 
Silky Cream Base (BAS-SLKC-01) natural gel base (BAS-NATGE-01), polyisobutene, 
mineral oil, phytosqualane and propylene glycol were purchased through Making 
Cosmetics Inc. (Redmond, WA, USA). Polysorbate 20 NF was purchased from LetCo 
Medical (Decatur, Al, USA). Polysorbate 80 was purchased through Fisher Scientific 
(Waltham, MA, USA). Sodium lauryl sulfate was purchased through Gallpot (St. Paul, 
Mn, USA). Regent free water was purchased from Corning (Corning, NY, USA). 
Simulgel NS was purchased from Seppic Inc. (Fairfeild, NJ, USA). Oleyl alcohol 
ethoxylate was purchased from Croda (Snaith, UK). 
High-Performance Liquid Chromatography (HPLC) Analysis  
Samples containing lipophilic surfactant were prepped for HPLC analysis using a C-18 
100 mg (part no: 12102001) solid phase extraction (SPE) column were purchased through 
Agilent Technologies (Salta Clara, CA, USA) to remove residual surfactant. Analytical 
HPLC was carried out using a Dionex UltiMate 3000 HPLC system equipped with a micro 
vacuum degasser, an autosampler, and a diode-array detector. Cannabidiol was 
quantified using high performance liquid chromatography. HPLC analysis was performed 
with an Thermo C18 column (250 × 4.6 mm, 5 μm) and a solvent system consisting of 
0.05% formic acid in water (A)/Acetonitrile (B) was used as the mobile phase using a 9 
minute isocratic method at 80% B and a flow rate of 0.6 mL/min. 
LC-MS method 
Various PAMPA samples were analyzed using both LC-UV and LC-MS analysis 
(Thermo Fisher ISQ system paired with a Dionex HPLC system). LC-MS analysis was 
performed with an Thermo C18 column (250 × 4.6 mm, 5 μm) and a solvent system 
consisting of 0.05% formic acid in water (A)/Acetonitrile (B) which was used as the 
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mobile phase with a 15 minute isocratic method at 80% B and a flow rate of 0.6 mL/min 
(Figure S1) 
Cannabidiol Stability in Solution 
The stability of CBD in a pH adjusted aqueous solution was determined through a 
stability test. Cannabidiol in 10% tween 20 (w/w) was added to PBS buffer that was 
adjusted to pH 4,5,6 and 7 . Each solution was prepared to a final concentration of 200 
µg/ml of CBD. Solutions were left at room temperature and constant light for 30 days. 
Samples of solution were taken at different time points. The concentration of CBD in 
solution was quantified using HPLC analysis and a linear regression of areas under the 
curve. (Figure S7) 
Cannabidiol Surfactant Solubility 
A panel of 4 surfactants, polyisobutene (PIB), polysorbate 20 (tween 20), polysorbate 80 
(tween 80) and sodium lauryl sulfate (SLS) were evaluated for their potential to solubilize 
cannabidiol in an aqueous solution (Figure S5,Figure S6). Each solution was prepared at 
surfactant concentrations of 1, 2, 5 or 10% (w/w); the final surfactant concentration used 
in the experiment was 10% (w/w). In a falcon tube, 5 mg of Cannabidiol and surfactant 
was added to 12 mL of phosphate buffer saline (PBS) or  phosphate buffer (PB). 
Solutions were shaken and left at room temperature for 24 hours. Solutions that did not 
have visible precipitation of cannabidiol were prepared for HPLC analysis using SPE and 
concentrations were evaluated using a standard linear regression (Figure S7). 
Parallel Artificial Membrane Permeability Assay (PAMPA) 
Pion’s suggested procedures were followed as stated in the instruction manual, version 
4. Briefly, test compounds and standards were prepared at 10 mM concentrations in 
DMSO. In the deep well plate provided by Pion, 1 mL of each pH adjusted buffer was 
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added to separate wells. For each pH, 5 µL of the 10 mM the 10 mM sample was added 
to 1 mL of pH adjusted buffer then mixed thoroughly with a pipette, diluting the sample to 
a final concentration of 50 µM. 200 µl of the diluted sample was added to the donor 
(bottom) plate from the Pion sandwich assay. Next, 200 µL of acceptor sink buffer was 
added in each well of the acceptor plate. The sandwich was assembled, and the plate 
was incubated at room temperature, with stirring for 5 hours undisturbed. After 
incubation, the UV profiles of the donor and acceptor plates were read on the 
SpectraMax plate reader connected to the PAMPA software. PAMPA software 
calculated the –log Pe values for each compound and standard using the UV profiles of 
the donor and acceptor plates. Standards were all within 0.25 of the expected value 




Formulations of CBD creams 
Two creams were used to evaluate CBD permeability in solution. The first, a 
commercially available cream from makingcosmetics.com was a silky cream base (BAS-
SLKC-01). CBD isolate powder (1% w/w) was added directly to this base and emulsified 
on a shearing instrument for 2.5 minutes. The second cream was formulated using 
ingredients in the compounding lab at the University of Rhode Island. The cream 
contained equal parts propylene glycol, phytosqualene and mineral oil to comprise 50% 
(w/w) of the total formulation. CBD isolate powder (1% w/w) was added directly to the 
propylene glycol, mixed thoroughly and added to the other oils. Next the surfactant, 
simulgel ns (7%) was added to the lipophilic phase mixture, followed by reagent free 
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water (42%). The cream was homogenized on a shearing instrument for 2.5 minutes. 
Each formulation was tested for physical evaluation between the thumb and index finger 
to ensure a smooth texture and no signs of phase separation. Formulations were then 
centrifuged 9 times at 5000 rpm in 5-minute intervals to confirm stability. Both 
formulations were stable and did not fully separate into 2 phases after centrifugation. 
Franz Cell Diffusion Assay 
One day prior to the assay, the receptor buffer was prepared in 50 mL falcon tubes and 
pre-warmed in a water bath at 32 °C overnight. 3% (w/w) surfactant was used in 1x PBS. 
Surfactant concentration was determined after solubility analysis. Tween 20 showed the 
best solubility for CBD (Figure S5). Depending on membrane brand and type, cellulose 
acetate membranes were hydrated one day prior to running the assay by submerging 
the membrane in 1x PBS in a beaker with parafilm covering the top (Figure S1). On the 
day of the assay, the Franz cell water bath was also pre-warmed to 32°C 30 minutes 
prior to beginning. After the water had been warmed, the pre-soaked membranes were 
applied to the apparatus using forceps. Next, 12 mL of acceptor buffer was added via 
pipette into each Franz cell, and 1 mL of pure CBD in DMSO or 200 mg of cream was 
added using a syringe. The tops of the cells were clamped and covered in parafilm to 
prevent evaporation. At each given timepoint, 600 µL of sample was removed from the 
spout of the Franz apparatus and replaced with 600 µL of fresh buffer.  
The In Vitro Release Testing (IVRT) Data Analysis 
Each 600 μL acceptor well example for IVRT analysis was first run through a C18 SPE 
column to remove any surfactant from the sample. Samples were then analyzed via 
HPLC, and the area under the curve (AUC) for the CBD peak was recorded. Elution time 
was compared with that of the CBD in the standard curve (Figure S8). A linear 
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regression of CBD standards was calculated (R2= 0.9759) and concentrations of CBD 
were interpolated. For the initial timepoint collected in the Franz cell assay, the formula 
used to calculate CBD released amount (drug concentration/1000 *12). For each 
timepoint following, the calculation was adjusted to account for the addition of fresh 
buffer added at each time point, for these timepoints the equation (drug 
concentration*12+0.6*(sum of sample concentrations)/1000) was used.  
RESULTS 
CBD shows favorable skin permeability in the PAMPA assay 
The skin permeability coefficient, Log Kp (cm/s) was used to evaluate the theoretical 
permeability of CBD through the skin (Table 1). This value was determined using an 
online computational model, SwissADME. CBD is considered to have moderate skin 
permeability with a Log Kp value of -3.59 cm/s. The positive PAMPA skin controls, 
warfarin, piroxicam, progesterone and verapamil all exhibited low skin permeability in the 
SwissADME predictor (Table S1). After this predictive measure, compounds were 
experimentally evaluated for passive permeability in the skin. 
 
T3 1 Table 1: In silico SwissADME predictive permeability of cannabidiol in the skin. 
sample -Log Kp  
( cm/s) 
Log Po/w -Log S 
(ESOL) 
-Log S (Ali) 
Cannabidiol 
(CBD) 
-3.59 3.90 -5.69 -7.17 
 
Compounds were evaluated for their permeability through a theoretical skin membrane 
using PAMPA at pH 6.5 and 7.4 (Figure 2). Warfarin was used as our low permeability 
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standard verapamil and piroxicam were used as our medium permeability standards, 
progesterone was used as our high permeability standard, and a pH control standard 
was also run. CBD showed similar permeability at both pH 6.5 and 7.4 with -LogPe 
values of 5.0194 ± 0.083 and 5.021 ± 0.045 respectively, suggesting it has moderate 




F4 2 Figure 2: CBD shows passive permeability in the Skin PAMPA model. The passive 
permeability of CBD was evaluated at two relevant pH levels 6.5 (A) and 7.4 (B). The 
controls warfarin and piroxicam exhibit low permeability, while progesterone and 
verapamil exhibit medium permeability. -Log Pe values for CBD at pH 6.5 and 7.4 were 
determined to be 5.0194 ± 0.083 and  5.021 ± 0.045 respectively. (n=6). 
CBD is soluble in surfactant Tween 20 
CBD solubility in an aqueous solution was evaluated using four surfactants at a final 
concentration of 10% w/w (Figure 3). The concentration of CBD in solution that did not 
come out of solution or crystallize was determined using HPLC analysis. Although no 
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apparent precipitation was observed, Polyisobutene (PIB) experienced minimal amount 
of CBD solubility in both PB and PBS buffer having 33.7 and 47.3 µg/mL of CBD in 
solution respectively (Figure S6). The concentrations of CBD in sodium lauryl sulfate and 
tween 80 solutions were also comparable to that of tween 20 (Appendix B). CBD 
solutions containing 10% tween 20 and PBS buffers were considered the ideal 
surfactant-solvent system, due to relatively high solubility and reproducibility. This 
solution contained about 378.4 μg of CBD per mL.    
 
F4 3 Figure 3: Tween 20 is the ideal surfactant to solubilize CBD in an aqueous 
solution Polyisobutene showed the least solubility potential for CBD in both PBS and 
PB buffer.  The concentrations are expressed as mean ± standard error (n=3), statistical 
significance was determined by analysis of variance (ANOVA).  Significance as 
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compared with tween 20, p ≤ 0.01 (*), p ≤ 0.001 (**), p ≤ 0.0001 (***) and p ≤ 0.00001 
(****). 
 
CBD in Tween 20 is skin permeable 
The theoretical skin permeability of pH adjusted CBD surfactant solutions was 
determined using PAMPA (Figure 4). Concentrations of CBD in the acceptor wells were 
determined using LC-MS analysis after 5 hours. CBD showed the least permeability in 
pH 5 with a maximum concentration of about 4.9 μg/mL. In contrast, CBD in the ideal 
surfactant-solvent solutions showed the most permeability at pH 7 with 7.4 μg/mL 
permeated.    
 
F4 4 Figure 4: CBD-Surfactant solution shows passive permeability at various 
pH’s. Assessment of skin passive permeability of CBD-Tween 20 solution determined 
via PAMPA. CBD exhibited variable permeability with pH change. Data is expressed as 
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mean ± standard error (n=3), statistical significance was determined by analysis of 
variance (ANOVA). Statistical significance between each pH (P=0.0039). 
 
CBD in Tween 20 is stable at pH of 5 
The stability of CBD in an aqueous solution was evaluated to determine the percent 
degradation of CBD at different pH’s (Figure 5). The stability suggests the optimal pH 
range of formulations containing CBD. Concentration of CBD was determined through 
HPLC analysis and quantified through a standard linear regression. CBD was added to a 
pH adjusted solution of PBS with 10% Tween 20 (w/w). Overall, CBD in solution showed 
the least amount of degradation at pH 5 with a cumulative degradation of 19% over 30 
days. In contrast, CBD in pH 7 solution showed the most degradation with 48.5% 
degrading over the 30-day period. CBD in pH solutions 4 and 6 showed similar trends 
with a degradation of about 30% and 29% over the 30 days respectively.  
 
F4 5 Figure 5: CBD is most stable at pH 5. The stability of a CBD-surfactant solution 
was evaluated at four pH’s 4, 5 , 6  and 7 . Degradation was confirmed through the 
accumulation of breakdown products and was expressed as percent cumulative 
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degradation over a 30-day timespan. Concentrations are expressed as mean ± standard 
error (n=3), statistical significance was determined by analysis of variance (ANOVA) with 
significance as compared with Day 0. 
In Vitro Permeation Test 
The permeability of CBD through a theoretical skin membrane was evaluated using the 
Franz cell diffusion model (Figure 6). Concentrations of permeated CBD were 
determined through HPLC analysis of the acceptor well. CBD showed passive diffusion 
through the theoretical skin membrane and reached its maximum diffusion concentration 
of 51.9 μg at 6 hours.   
 
 
F4 6 Figure 6: In vitro permeability profile of Cannabidiol (CBD) in sterile DMSO obtained 
using  Franz diffusion cells (n = 9). 
 
In Vitro Release Testing of CBD Formulations 
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The in vitro CBD release of two different cream formulations was tested using the Franz 
cell diffusion assay (Figure 7). The final CBD content in the formulations was 
approximately 1% (w/w). The cream formulation (200 mg) of cream was loaded onto 
each cellulose acetate membrane, HPLC analysis was taken of the acceptor well 
following each timepoint. CBD showed passive diffusion through a theoretical skin 
membrane in a cream formulation.  Further analysis is necessary to ensure CBD 
permeability through human skin.  
 
F4 7 Figure 7: In vitro release profiles of CBD formulations obtained using Franz 
diffusion cells (n=3). The in vitro drug release profiles of CBD EmulGel Cream (A) and 




 Cannabidiol’s extensive use in cosmetics necessitates further evaluation into the 
stability and permeability of this metabolite through the skin. Cannabinoids are 
susceptible to UV degradation, chemical rearrangements, and oxidation.24 Lindholst 
determined that when organic solvents, such as ethanol and chloroform are used, both 
temperature and light exposure influence the stability of cannabinoids.25 However, most 
of the studies that have been completed investigate the resin forms of Cannabis or the 
alcohol extracts. In skincare, alcohol extracts with solvent present and pure resin are 
rarely used. Rather, the lipophilic cannabinoids would be incorporated into aqueous 
based products using surfactants, or simply added to creams without surfactants. It is 
well established that light and temperature play the most significant role in 
degradation.25,26 We found that in a PBS and 10% w/w Tween 20 solution, which is more 
relevant in skincare formulations than alcoholic preparations, CBD shows the most 
degradation at pH 6 and pH 7 compared to pH 4 and pH 5 (Figure S7). Many skincare 
products are already formulated to be slightly acidic, often using ingredients such as 
citric acid to maintain barrier function of the acid mantle on the skin.27  
 CBD was evaluated with multiple in vitro assays to evaluate the passive 
permeability of CBD through biomimetic skin membranes. The first assay employed was 
the parallel artificial membrane permeability assay (PAMPA). Using this method, CBD 
permeability was compared to the control compounds provided with the assay with well-
established pharmacokinetics. CBD showed a similar permeability profile with the 
endogenous steroid progesterone.  A -Log Pe of 5.0194 was measured for the pH of 6.5, 
and a -LogPe of 5.021 at pH 7.4 suggesting CBD is moderately permeable through the 
skin. This aligns well with the results from the in silico prediction software SwissADME 
which predicted the permeability to be -3.59 (cm/s). 
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 Conceptually similar to PAMPA, the Franz cell diffusion assay was employed to 
determine the rate at which CBD penetrated synthetic skin membranes using in vitro 
release testing (Figure S8). After completion of a membrane compatibility test (Figure 
S3), SUPOR PES membranes were the most compatible with CBD, and the membranes 
did not interfere with the release of the compound. Commercially available gel and 
cream bases were purchased from makingcosmetics.com for initial evaluation for 
permeability studies. Due to the popularity of CBD creams, and the higher penetration, 
only creams were evaluated further in this study (Figure S2). When comparing 
formulations of CBD in a commercially available formulation and an in-house 
formulation, emul-gel cream, the in vitro release testing indicated the release of CBD in 
our formulation was much higher compared to the Making Cosmetics Inc. cream (Figure 
7). Discrepancies in permeability may be due to non-uniformity of CBD in formulation of 
the commercially available cream due to the order of incorporation of the CBD later in 
the formulation process compared to cream formulated in our laboratory where CBD can 
be incorporated into an oil medium prior to addition of other ingredients. Quantification of 
CBD initial concentrations in the commercially available product indicated that CBD 
isolate powder was not fully dissolved into the formulation. Excipient concentration for 
the making cosmetics cream is proprietary. A larger aqueous phase may account for 
discrepancies in uniformity and could allow for CBD to crash out of solution. This issue 
may be avoided in the future with the use of a carrier oil that is compatible with both the 
drug and formulation. Conversely, CBD isolate powder was added directly to the 
lipophilic phase of the emul-gel cream and concentrations of CBD in formulation were 
within expected range. The way in which this emul-gel cream was formulated likely 
affected both stability and permeability of CBD in formulation. Permeability may have 
also been influenced by the presence of penetration enhancing oils in the lipophilic 
phase of the emul-gel cream. Propylene glycol, an excipient used in formulating, has 
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been shown to enhance transdermal drug permeability.28 PAMPA analysis of the 
compounds at pH 6.5 and 7.4 showed similar permeability patterns (Figure 6). When 
different surfactants were used in the PAMPA assay, a difference in pH permeability 
dependence was observed. Tween 20 and Tween 80 showed better solubility at pH 6 
and pH 7 compared to those at the lower pH values tested. Sodium lauryl sulfate 
showed significantly better permeation at pH 7 compared to the other pH values (Figure 
S4)  
CONCLUSION 
 Cannabidiol’s popularity in cosmeceuticals warrants an investigation into the 
stability and permeability through artificial skin membranes. In this study, CBD showed 
moderate skin permeability in the PAMPA assay using both the pure compound and 
cream formulations. The stability of CBD can be increased by keeping the product cool, 
out of light, and at lower pH. At pH 5, CBD is the most stable in a solution of PBS with 
Tween 20 as a surfactant. Highly lipophilic cream formulations should be considered for 
deeper penetration of CBD. Further evaluation is necessary to assess CBD permeability 
in human skin. 
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 As previously known diseases evolve and progress, or new diseases emerge, we 
look to the diverse chemistry of nature for new therapeutics. Natural products have been 
used for centuries in traditional Chinese medicine, Ayurvedic medicine, Native American 
medicine and more, and there remains a significant number of untapped sources. 
However, natural product extracts are extremely chemically diverse and it is essential to 
have methodologies in place to highlight drug candidates and weed out other 
metabolites as early as possible. Employing these methodologies early in the drug 
screening process can save billions of dollars, thousands of animals’ lives, and hundreds 
of hours of precious time.  
 Screening natural product libraries for drug leads is a valuable tool for increasing 
the chances of a hit from either a single metabolite or a family of metabolites. The value 
of this drug screening pipeline can be enhanced when orthogonal assays are 
incorporated into the drug screening that consider common roadblocks in the drug 
development pipeline. Evaluating a drug candidates permeability through biological 
membranes is an integral component of drug development, and recent tools have been 
developed for in vitro analysis. The development of the Principal Rhode Island 
Secondary Metabolite (PRISM) library from the plants in the University of Rhode Island’s 
Heber W. Youngken Jr. Medicinal Plant Garden was the first step towards developing a 
screening platform. The utility of the PRISM library was then demonstrated through 
antimicrobial testing of two persistent pathogens Staphylococcus aureus and 
Escherichia coli. A metabolite isolated from the tulip tree (Liriodendron tulipifera) named 
laurenobiolide showed promising activity as a terpene antibiotic to combat methicillin 
resistant S. aureus infections and a metabolite from saffron (Crocus sativus) showed 
promising activity in reversing bacteria quiescence, a phenomenon contributing to 
persistent and reoccurring UTIs.   
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 Not every assay is compatible with crude extract testing. In the case of cell 
culture assays for example, it is much simpler to either have a pure compound library or 
some rarified mixtures of compounds. The benefit of evaluating a mixture of compounds 
includes less time spent in the process of generating the library and an increased 
chance of discovering a new chemical entity with bioactivity. This was demonstrated in 
workflows evaluating a cyanobacteria chromatography library for anti-inflammatory 
potential. Two new members of the micropeptin family were discovered as anti-
inflammatory peptides.  
 My research has also combined multiple methods of library screening within the 
same pipeline; this included in silico screening for drug likelihood, in vitro screening for 
permeability, and in vitro screening for bioactivity. This resulted in the discovery of a 
cyanobacteria metabolite, unnarmicin D which acts as a delta and mu opioid ligand with 
anti-inflammatory properties to murine microglia cells. These results could have further 
implications in the fight against the opioid epidemic as delta opioid agonists are less 
addictive pain alternatives to the traditional mu opioidactivators such as morphine as 
well as a way to combat the development of neurodegenerative diseases.   
 Lastly, the commonly used cosmeceutical metabolite from the Cannabis sativa 
plant cannabidiol, contributes millions of dollars in sales of skincare supplements 
annually, but the permeability through the skin has not been well evaluated. Two in vitro 
assays were utilized to determine the passive permeability of CBD through the skin, 
which will have implications in future product formulations.  
 These data combined provide insight into multiple diseases and the 
methodologies discussed herein can be applied to a variety of synthetic and small 
molecule natural products. Moreover, these results support the initial hypothesis that 
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early incorporation of permeability screening into drug discovery workflows will enhance 
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A1 2 Figure S2. Comparison of anti-oxidant activity between aerial and root methanol 
extracts of Echinacea purpurea. Quercetin was used as a positive control.  
 
A1 3 Figure S3. Comparison of anti-oxidant activity among the chromatography fractions 
generated from Echinacea purpurea root methanol extract. SPE 1 clearly showed 
strongest anti-oxidant activity and was chosen for further HPLC and MS experiments. 






A1 4 Figure S4. Comparison of initial and improved HPLC chromatograms of St. John’s 

















A1 5 Figure S5. Mass spectrum of Berberrus thumbergii sample indicating the likely 





A1 6 Figure S6. Analysis of St. John’s Wort samples by the afternoon teaching lab 
group. TIC and UV analysis at 210 nm and 254 nm are shown. MS analysis identified a 






A1 7 Figure S7. Analysis of St. John’s Wort samples by the morning teaching lab group. 
TIC and UV analysis at 210 nm and 254 nm are shown. MS analysis identified a 







A1 8 Figure S8. Antioxidant bioassay plates from both the morning hops group (left 
plate) and the afternoon hops group (right plate). The plates tested three SPE fractions 
with quercetin used as a positive control. Concentrations begin at 1 mg/mL in row A and 
decrease 2-fold in each row of the plate moving toward the bottom of the plate. Both 
groups identified SPE 1 as the fraction with the strongest antioxidant activity. The SPE 1 









A1 9 Figure S9. LC-UV-MS chromatograms of SPE 1 fraction from both the morning and 
afternoon groups who were studying hops extracts (UV = 254 nm). Mass spectra of the 
major peaks (highlighted in pink) are shown in Figure S10. Methods were identical in 
morning and afternoon groups. 
 
A1 10 Figure S10. MS spectra of the major peaks from LC-UV-MS analysis, which was 
shown in Figure S9 (peak highlighted in pink). Many identical ions can be observed in 
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A2 1 Figure S1: HPLC chromatogram of the crude methanol extract of the tulip tree 
(Liriodendron tulipifera). Mobile phase consisted of water and acetonitrile with 0.5% 
formic acid. The method was 70 minutes long with a 10 minute hold on the starting 
conditions of 15% CH3CN: 85% H2O, followed by a gradient which ended at 45 minutes, 
followed by a 100% organic hold for 20 minutes and a 5 minute reconditioning phase at 










A2 2 Figure S2: (A) The initial antibacterial disc diffusion assay highlighted two main 
peaks in the lipophilic fractions of the tulip tree, upon isolation of each peak, the later 
eluting peak showed the most antibacterial activity towards S. aureus.  (B) The purity of 
both major peaks was checked on a phenyl hexyl column. Peak 1 was a single pure 
compound, and peak 2 was two distinct peaks. The isocratic method was 55% 
CH3CN /45% H2O with 0.05% formic acid added to each solvent at a flow rate of 3 
mL/min (C) The three isolated peaks were re-tested to determine the active compound. 
Peak 2.1 was determined to be the active compound, the other compounds did not show 
anti-MRSA activity. Methanol was used as the diluent and the negative control. 
Gentamicin sulfate was used as the positive control. Left plate is dosed at 20 µg and 
right plate is dosed at 5 µg.  
 
 
A2 3 Figure S3: 13C NMR spectrum of peak 2 (500 MHz, DMSO-d6) prior to separation 
via phenyl hexyl column, showing an abundance of signals compared to what would be 



















A2 6 Figure S6: 1H NMR spectrum of peak 2.2, identified as tulipinolide (500 MHz, CDCl3).  
 
 
A2 7 Figure S7: High resolution mass spectrometry measurement of laurenobiolide, 




A2 8 Figure S8: HPLC chromatogram highlighting the active antibacterial compound 












A2 9 Figure S9: Results of E. coli quiescent activation testing with PRISM library 
samples. Positive control consists of co-spotting lysine and methionine at 1 mM. 69.3% 
of extracts tested (79/114) showed some level of quiescent reversing activity, the 
remaining 30.7 % of extracts did not. Samples were prepared at 10 mg/mL in (CH3)2SO 
with 10 µL spots.  
 
A2 10 Figure S10: Separation of saffron fraction 20% H2O: 80% CH3CN using HPLC 
with fraction collector. Four pools of compounds were collected for retesting on the 
quiescence assay (blue shaded areas). The method used a C18 semi-preparative 
column with water and acetonitrile as the mobile phase. Gradient method beginning at 




A2 11 Figure S11: Individual compounds were isolated from the active fraction pool. 
Method consisted of water and acetonitrile as the mobile phase with 0.5% formic acid. 
Gradient method of 5% CH3CN  30% CH3CN. A Phenomenex phenyl hexyl 
semipreparative column was used for isolation. Fraction 1 was identified as the active 




A2 12 Figure S12: Compounds isolated from fraction 1 showing compounds 4 and 5 with 
the most potent quiescence reversing activity. Samples were tested at 1 mg/ mL with 10 





A2 13 Figure S13: Titration of compound 4 (upper left) and compound 5 (upper right) 
from Crocus sativus. Compound 4 showed the strongest activity when the dose was 




A2 14 Figure S14: HRESIMS analysis of the active compound 4. 
 
A2 15 Figure S15: MS/MS spectrum of the active compound 4 fragmenting the precursor 
m/z 319.1486.  
 
 
A2 16 Figure S16: 1H NMR spectrum of the active compound 4 (500 MHz, DMSO) 
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Table S1. NMR data for micropeptin 957 (500 MHz for 1H NMR, DMSO-d6) (2). 
Figure S1. Structures of micropeptins 982 (1), 957 (2), and 996. 
Figure S2. Cell viability of Biosortia chromatography fractions tested against BV-2 
murine microglial cells. 
Figure S3. Ability of Biosortia chromatography fractions to reduce nitric oxides species 
(NOS) in BV-2 murine microglial cells. 
Figure S4. Full MS/MS network of fraction D29. Analysis was performed using the 
software available at the GNPS: Global Natural Product Social Molecular Networking 
website. Node size is indicative of ion count. 
Figure S5. HPLC isolation of compounds in chromatography fraction D29. 
Figure S6. Final purification of compounds 1 (6.1) and 2 (6.2) from fraction D29 peak 6. 
Figure S7. 1H NMR spectrum of micropeptin 996 (500 MHz, DMSO-d6). 
Figure S8. 13C NMR spectrum of micropeptin 996 (125 MHz, DMSO-d6). 
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Figure S9. HRESIMS of micropeptin 996, m/z 1019.4854 [M+Na]+. 
Figure S10. MS/MS of micropeptin 996. 
Figure S11. 1H NMR spectrum of micropeptin 982 (1) (500 MHz, DMSO-d6). 
Figure S12. 13C NMR spectrum of micropeptin 982 (1) (125 MHz, DMSO-d6). 
Figure S13. HSQC spectrum of 1. 
Figure S14. HMBC spectrum of 1. 
Figure S15. COSY spectrum of 1.  
Figure S16. TOCSY spectrum of 1. 
Figure S17. NOESY spectrum of 1. 
Figure S18. HRESIMS of micropeptin 982 (1), m/z 1005.4698 [M+Na]+. 
Figure S19. MS/MS of micropeptin 982 (1). 
Figure S20. 1H NMR spectrum of micropeptin 957 (2) (500 MHz, DMSO-d6). 
Figure S21. COSY spectrum of 2. 
Figure S22. TOCSY spectrum of 2. 
Figure S23. NOESY spectrum of 2.  
Figure S24. HRESIMS of micropeptin 957 (2), m/z 980.4858 [M+Na]+. 
Figure S25. MS/MS of micropeptin 957 (2). 
Figure S26. Marfey’s analysis of micropeptin 982 (1). 
Figure S27. Marfey’s analysis of micropeptin 957 (2). 
Figure S28. Dose-responses of micropeptin 996, 1, and 2 tested for plasmin inhibition. 
 
 
STA1 1 Table S1. NMR data for micropeptin 957 (500 MHz for 1H NMR, DMSO-d6) (2). 
 
Position δH, mult, J (Hz) COSY/TOCSY  
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Figure S1. Structures of micropeptins 982 (1), 957 (2), and 996. Key 2D NMR 
correlations are shown for 1 and 2. Additionally, NOE correlations are shown for the Ahp 










A5 2 Figure S2. Cell viability of Biosortia chromatography fractions tested against BV-2 





A5 3 Figure S3. Ability of Biosortia chromatography fractions to reduce nitric oxides 






















A5 4 Figure S4. Full MS/MS network of fraction D29. Analysis was performed using the 
software available at the GNPS: Global Natural Product Social Molecular Networking 















































































































































































































































































































































































































A5 26F Figure S26. Marfey’s analysis of micropeptin 982 (1) with L-phenylalanine 
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STA3 1 Table S1: Trichodesmium metabolites SWISS ADME profiles with conditional formatting 
for pharmacokinetic data. 
 
 
STA3 2 Table S2: Metabolites of interest based on in silico screening. Two polyketides 
and one cyclic peptide were highlighted as the most likely to be drug candidates based 





STA3 3 Table S3: Neurotherapeutic target predictions for the top ADME metabolites.  
The three drug-like molecules from SWISS ADME were further evaluated using SWISS 
Target Predictor. Focusing only on neuropharmacological targets, the small polyketide, 
tricholactone (GH2I1), showed a low probability of being a dopamine transporter. 
Trichophycin B (EF1E) showed low to moderate probability of being a noradrenaline 
transporter, serotonin transporter, and/or a dopamine transporter. Unnarmicin D 
(GH2C1) showed moderate to high probability of containing opioid receptor binding 
activity to either the delta or mu opioid receptor.  
 
 
STA3 4Table S4: Multiple-reaction-monitoring transitions 
 
Compound MRM-transition (parent ion/product ion) 
Theophylline 181/110 
Verapamil 455/289 
GH2D8  499/330 
GH2N1  616/598 




STA3 5 Table S5: All RMSD, S-values, and PLB values for molecular modeling data. Red highlight 

















A3 2 Figure S2: The fractionation workflow for cyanobacteria collections. Crude extract 
is obtained then subjected to repeat extractions using 2:1 DCM:Methanol followed by 
further rareification into fractions A-I using vacuum liquid chromatography and stepped 
gradients of hexanes, ethyl acetate, and methanol. Fraction G was used to confirm the 






A3 3 Figure S3: BV2 cell viability after treatment with cyanobacterial compounds. The 
effects of the cyanobacteria metabolites on the viability of BV-2 cells was evaluated 
using Cell Titer Glo assay. Cells were dosed with 10 µM, 5 µM and 1 µM of pure 







A3 4 Figure S4: Structure comparison of the synthesized unnarmacin D analog and the 
natural product. Due to limitations in compound unnarmicin D (GH2C1), the peptide was 
synthesized. The synthetic compound and the originally isolated natural product are the 



















A3 7 Figure S7: Mass spectrometry of the synthesized unnarmicin D. The synthesized 


































A3 9 Figure S9: Anti-inflammatory activity of linear unnarmicin D, the natural product, 
and synthetic. Griess assay results showing the total NOS concentration in cell 
supernatant after treatment with unnarmicin D derivatives at 5 µM for one hour followed 
by LPS activation of BV2 cells for 24 hours. Significance as compared with synthetic 
unnarmicin D using ANOVA with Dunnett’s multiple comparison procedure, p ≤ 0.03 
(*), p ≤ 0.002 (**), p ≤ 0.0002 (***) and p ≤ 0.0001 (****). All three metabolites showed 











A3 10 Figure S10: Base hydrolysis of unnarmicin D results in a linear peptide. This 












A3 11 Figure S11: HPLC analysis of the base hydrolyzed unnarmicin D. 
 
A3 12 Figure S12: MS analysis of the base hydrolyzed unnarmicin D. The sodiated 








A3 13 Figure S13: 1H NMR spectrum of the base hydrolyzed synthetic unnarmicin D 









A3 14 Figure S14: A.) The MOR (6DDF) binding interactions of the base hydrolyzed 
synthetic unnarmicin D. B.) The DOR (4N6H) binding interactions of the base hydrolyzed 




A3 15 Figure S15: Unnarmicin D modeled in the binding pocket of three DOR crystal 
structures. A.) The agonist bound conformation, PDB 6PT2, B.) The antagonist bound 






A3 16 Figure S16: Unnarmicin D derivatives modeled with a methyl group in place of the 




A3 17 Figure S17: A-B. The agonist bound MOR (PDB 5C1M) with water molecules 
present. C-D.The unbound DOR receptor (4N6H) with water molecules and a sodium ion 





A3 18 Figure S18: Histogram of values representing the agonist radioligand binding of 
Unnarmicin D to the MOR and the DOR showing the pIC50 for each receptor.  
 
A3 19 Figure S19: Radioligand binding assay for unnarmicin D on the delta opioid 















A3 20 Figure S20: Radioligand binding assay for unnarmicin D on the mu opioid 















A3 21 Figure S21: Radioligand binding assay comparison of the synthetic linear 







































A3 26 Figure 
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Warfarin -6.00 -6.26 2.41 -3.70 -3.77 
Piroxicam -5.67 -6.15 1.67 -4.01 -4.99 
Verapamil -5.65 -6.38 4.50 -4.46 -4.83 












Figure S1. CBD PAMPA LC-MS Chromatogram. The passive permeability of CBD 
through a theoretical skin membrane was determined using the PAMPA assay. The 
presence of CBD in the acceptor buffer was determined through LC-MS analysis and 




Figure S2. CBD stability test HPLC chromatogram. The stability of CBD in surfactant-buffer 
solution. The degradation of CBD in a surfactant-buffer solution was confirmed through HPLC 
analysis, using a standard elution time ~6 minutes and UV detection of 210 nm. CBD 
degradation was monitored from day 0 (1) to day 30 (2).  Degradation of API was confirmed 
through reduction of CBD peak area and the accumulation of degradative product peaks eluting 




Figure S3: CBD solubility in potential Franz cell acceptor buffers. A solution of PBS 
buffer containing 3% (w/w) tween-20 (T20) was determined to be the optimal solvent 
system that allows for the passive diffusion of CBD through a synthetic membrane.  
Solvent systems containing ethanol (Etoh) and Oleyl alcohol ethoxylate (OAE) at various 





Figure S4. CBD solubility test HPLC chromatogram. CBD in a 10% (w/w) poly 
isobutene – PBS buffer solution (1), 10% (w/w) poly isobutene – PB buffer solution (2) 
and a 10% (w/w)Tween 20-PBS solution (3) were evaluated to determine the ideal 
surfactant solvent system to solubilize the API. The amount of CBD in solution was 








A4 1 Figure S5: The permeability profile of CBD in 10% tween-20 surfactant solution 




Figure S6.CBD IVRT HPLC chromatogram. CBD Showed passive permeability in the 
Franz Cell diffusion assay. The permeability profile of CBD through a synthetic skin 
membrane was determined using the Franz cell diffusion assay. The presence of CBD 
was confirmed through HPLC analysis, using the average elution time of ~7.2 minutes 
and UV detection of 210 nm. At each time point 30 minutes (1), 1 hour (2), 2 hours (3), 4 




A4 2 Figure S7: CBD compatibility test using the Franz cell assay (n=3). Receptor buffer 





A4 3  
Figure S8:  In vitro release testing (IVRT) of CBD in commercially available cream silky 
cream (BAS-SLKC-01) and gel (BAS-NATGE-01) formulations (Making cosmetics) in the 
Franz cell assay, (n=3). CBD formulation permeability was achieved with the use of a 











Figure S9: CBD-Surfactant solution shows passive permeability in various pH’s. 
Assessment of skin passive permeability of CBD-Tween 80 & and CBD- Sodium Lauryl 
Sulfate solution determined by PAMPA. CBD exhibited variable permeability with pH 
change. Data is expressed as mean ± standard error (n=3). 
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